[go: up one dir, main page]

WO2024258995A2 - Psychoplastogènes de tétrahydroazépine fusionnés et leurs utilisations - Google Patents

Psychoplastogènes de tétrahydroazépine fusionnés et leurs utilisations Download PDF

Info

Publication number
WO2024258995A2
WO2024258995A2 PCT/US2024/033653 US2024033653W WO2024258995A2 WO 2024258995 A2 WO2024258995 A2 WO 2024258995A2 US 2024033653 W US2024033653 W US 2024033653W WO 2024258995 A2 WO2024258995 A2 WO 2024258995A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
compound
heterocycloalkyl
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/033653
Other languages
English (en)
Other versions
WO2024258995A3 (fr
Inventor
Milan Chytil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delix Therapeutics Inc
Original Assignee
Delix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delix Therapeutics Inc filed Critical Delix Therapeutics Inc
Publication of WO2024258995A2 publication Critical patent/WO2024258995A2/fr
Publication of WO2024258995A3 publication Critical patent/WO2024258995A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds for the treatment of conditions, diseases, or disorders that would benefit from promoting neuronal growth and/or improving neuronal structure.
  • ketamine is capable of rectifying deleterious changes in neuronal structure that are associated with neurological diseases and disorders.
  • Such structural alterations include, for example, the loss of dendritic spines and synapses in the prefrontal cortex (PFC) as well as reductions in dendritic arbor complexity. Furthermore, pyramidal neurons in the PFC exhibit top- down control over areas of the brain controlling motivation, fear, and reward. Psychedelic psychoplastogens have demonstrated antidepressant, anxiolytic, and anti-addictive effects of in the clinic.
  • A, B, and C are each independently NR 7 , CHR 6a , or CHR 6b , wherein one of A, B, and C is NR 7 and the remaining two of A, B, and C are CHR 6a or CHR 6b ; each of R 1 , R 2 , R 3 , R 4 , and R 5 is independently hydrogen, halogen, -OR a , -SR a , -NR b R c , - CN, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, heteroaryl, arylalkyl, cycl
  • R 7 is Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted;
  • R 6a and R 6b are each independently hydrogen, halogen, -OR a , -SR a , -NR b R c , -CN, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or R 7 is taken together with either R 6a or R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring; or R 6a and R 6b are taken together with the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring or an optionally substituted cyclo
  • R b and R c are each independently hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci- ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, arylalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or R b and R c are taken together with the nitrogen to which they are attached to form an optionally substituted heterocycloalkyl ring; wherein,
  • R 7 and R 6a are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 7 and R 6b are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 6a and R 6b are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring or an optionally substituted cycloalkyl ring.
  • A is CHR 6a
  • B is NR 7
  • C is CHR 6b
  • R 6a is hydrogen
  • R 7 is taken together with R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R
  • the compound of Formula (I) has the structure of Formula (IA):
  • A is CHR 6a ; B is NR 7 ; C is CHR 6b ; R 6b is hydrogen; and R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R, and wherein the compound of Formula (I) has the structure of Formula (IB):
  • a and B are each independently NR 7 or CHR 6a , wherein one of A and B is NR 7 and the other of A and B is CHR 6a ;
  • R 2 is hydrogen, -Br, -OR a , -SR a , -CN, C2-ealkyl, Ci-eheteroalkyl, C2-ehaloalkyl, Ci- ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted;
  • R 7 is Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted;
  • R 8 is hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted; each R 6a and each occurrence of R 6b is independently hydrogen, halogen, -OR a , -SR a , - NR b R c , -CN, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl,
  • R b and R c are each independently hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci- ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, arylalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or
  • R b and R c are taken together with the nitrogen to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 7 and R 6a are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 7 and one occurrence of R 6b are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 6a and one occurrence of R 6b are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring or an optionally substituted cycloalkyl ring; or
  • a and B are each independently NR 7 or CHR 6a , wherein one of A and B is NR 7 and the remaining is CHR 6a ;
  • R 3 is hydrogen, fluoro, chloro, -OR a , -SR a , -NR b R c , -CN, Ci-ealkyl, Ci-eheteroalkyl, Ci- ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, arylalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted;
  • R 7 is Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted;
  • R 8 is hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted; each R 6a and each occurrence of R 6b is independently hydrogen, halogen, -OR a , -SR a , - NR b R c , -CN, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl,
  • R b and R c are each independently hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci- ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, arylalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or
  • R b and R c are taken together with the nitrogen to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 7 and R 6a are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 7 and one occurrence of R 6b are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 6a and one occurrence of R 6b are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring or an optionally substituted cycloalkyl ring; or
  • A is NR 7 ; B is CHR 6a ; R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R, and wherein the compound of Formula (IIA) has the structure of Formula (IIA-1):
  • X is NR 8 , n is 0, m is 1, and the compound of Formula (IIA-1) has the structure of Formula (IIA-2):
  • A is NR 7
  • B is CH2
  • R 7 is taken together with one occurrence of R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R
  • the compound of Formula (IIA) has the structure of Formula (IIA-3):
  • A is NR 7 ; B is CHR 6a ; R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R, and wherein the compound of Formula (IIB) has the structure of Formula (IIB-1):
  • X is NR 8 , n is 0, m is 1, and the compound has the structure of Formula (IIB -2):
  • A is NR 7
  • B is CH2
  • R 7 is taken together with one occurrence of R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R
  • the compound of Formula (IIB) has the structure of Formula (IIB-3):
  • X is NR 8 , n is 0, m is 1, and the compound has the structure of Formula (IIB -4):
  • a pharmaceutical composition comprising a disclosed herein (e.g., a compound Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA- 2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), or a pharmaceutically acceptable salt, isotopically enriched variant, or solvate thereof, and at least one pharmaceutically acceptable excipient.
  • a disclosed herein e.g., a compound Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA-1), (IIA- 2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), or a pharmaceutically acceptable salt, isotopically enriched variant, or
  • the compounds disclosed herein, or a pharmaceutically acceptable salt thereof are formulated for administration to a mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, dermal administration, or ophthalmic administration.
  • the compound disclosed herein, or a pharmaceutically acceptable salt thereof is in the form of a tablet, a pill, a capsule, a liquid, a suspension, a gel, a dispersion, a solution, an emulsion, an ointment, or a lotion.
  • described herein is a method of promoting neuronal growth in a mammal comprising administering to the mammal a compound described herein, or any pharmaceutically acceptable salt or solvate thereof.
  • a method of improving neuronal structure comprising administering to the mammal a compound provided herein, or a pharmaceutically acceptable salt or solvate thereof.
  • a method of method of modulating the activity of 5-hydroxytryptamine receptor 2 A (5-HT2A) receptor in a mammal comprising administering to the mammal a compound provided herein, or any pharmaceutically acceptable salt or solvate thereof.
  • 5-hydroxytryptamine receptor 2 A 5-HT2A
  • described herein is a method of treating a disease or disorder in a mammal that is mediated by the action of 5-hydroxytryptamine (5-HT) at 5-hydroxytryptamine receptor 2A (5-HT2A) comprising administering to the mammal a compound provided herein, or any pharmaceutically acceptable salt or solvate thereof.
  • described herein is a method of treating a disease or disorder in a mammal that is mediated by the loss of synaptic connectivity, plasticity, or a combination thereof comprising administering to the mammal a compound provided herein, or a pharmaceutically acceptable salt or solvate thereof.
  • the disease or disorder is neurological disease or disorder.
  • a method for treating neurological disease or disorder in a mammal comprising administering to the mammal a compound represented by the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), or a pharmaceutically acceptable salt, isotopically enriched variant, or solvate thereof.
  • the neurological disease or disorder is a neurodegenerative disease or disorder, a neuropsychiatric disease or disorder, or a substance use disease or disorder.
  • the neurological disease or disorder is an injury.
  • the neurological disease or disorder is selected from the group consisting of an anxiety disorder, a mood disorder, a psychotic disorder, a personality disorder, an eating disorder, a sleep disorder, a sexuality disorder, an impulse control disorder, a substance use disorder, a dissociative disorder, a cognitive disorder, a developmental disorder, and a factitious disorder.
  • the mammal is a human.
  • an effective amount of the compound described herein, or a pharmaceutically acceptable salt thereof is: (a) systemically administered to the mammal; and/or (b) administered orally to the mammal; and/or (c) intravenously administered to the mammal; and/or (d) administered by injection to the mammal.
  • further embodiments comprising single administrations of an effective amount of the compound, including further embodiments in which the compound is administered once a day to the mammal or the compound is administered to the mammal multiple times over the span of one day.
  • the compound is administered on a continuous dosing schedule.
  • the compound is administered on a continuous daily dosing schedule.
  • Articles of manufacture which include packaging material, a formulation within the packaging material (e.g. a formulation suitable for topical administration), and a label that indicates that the compound or composition, or pharmaceutically acceptable salt, or solvate thereof, is used for promoting neuronal growth and/or improving neuronal structure, or for the treatment, prevention or amelioration of one or more symptoms of a disease or disorder that is associated with promoting neuronal growth and/or improving neuronal structure, are provided.
  • a formulation within the packaging material e.g. a formulation suitable for topical administration
  • a label that indicates that the compound or composition, or pharmaceutically acceptable salt, or solvate thereof, is used for promoting neuronal growth and/or improving neuronal structure, or for the treatment, prevention or amelioration of one or more symptoms of a disease or disorder that is associated with promoting neuronal growth and/or improving neuronal structure.
  • the present disclosure provides non-hallucinogenic compounds useful for the treatment of a variety of neurological diseases and disorders as well as increasing neuronal plasticity.
  • Psychedelic compounds promote structural and functional neural plasticity in key circuits, elicit therapeutic responses in multiple neuropsychiatric disorders, and produce beneficial neurological effects that can last for months following a single administration.
  • Compounds capable of modifying neural circuits that control motivation, anxiety, and drug-seeking behavior have potential for treating neurological diseases and disorders that are mediated by the loss of synaptic connectivity and/or plasticity.
  • such compounds are likely to produce sustained therapeutic effects because, for example, of the potential to treat the underlying pathological changes in circuitry.
  • 5-HT2A antagonists abrogate the neuritogenesis and spinogenesis effects of hallucinogenic compounds with 5-HT2A agonist activity, e.g., DMT, LSD, and DOI, demonstrating the correlation of 5-HT2A agonism and the promotion of neural plasticity (Ly et al., 2018; Dunlap et al., 2020).
  • the hallucinogenic and dissociative potential of such compounds has limited the use of these compounds in the clinic for neurological diseases, such as, for example, neuropsychiatric diseases. (Ly et al., 2018)
  • non-hallucinogenic analogs of psychedelic compounds such as, for example, lisuride and sumatriptan
  • neurodegenerative diseases e.g., Alzheimer’s disease and Parkinson’s disease
  • headaches e.g., migraines
  • Ci-C x (or Ci- X ) includes C1-C2, C1-C3 . . . Ci-C x .
  • a group designated as "C1-C4" indicates that there are one to four carbon atoms in the moiety, i.e. groups containing 1 carbon atom, 2 carbon atoms, 3 carbon atoms or 4 carbon atoms.
  • C1-C4 alkyl indicates that there are one to four carbon atoms in the alkyl group, i.e., the alkyl group is selected from among methyl, ethyl, propyl, Ao-propyl, //-butyl, Ao-butyl, ec-butyl, and /-butyl.
  • Alkyl generally refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, such as having from one to fifteen carbon atoms (e.g., C1-C15 alkyl). Unless otherwise state, alkyl is saturated or unsaturated (e.g., an alkenyl, which comprises at least one carbon-carbon double bond). Disclosures provided herein of an “alkyl” are intended to include independent recitations of a saturated “alkyl,” unless otherwise stated. Alkyl groups described herein are generally monovalent, but may also be divalent (which may also be described herein as “alkylene” or “alkylenyl” groups).
  • an alkyl comprises one to thirteen carbon atoms (e.g., C1-C13 alkyl). In certain embodiments, an alkyl comprises one to eight carbon atoms (e.g., Ci-Cs alkyl). In other embodiments, an alkyl comprises one to five carbon atoms (e.g., C1-C5 alkyl). In other embodiments, an alkyl comprises one to four carbon atoms (e.g., C1-C4 alkyl). In other embodiments, an alkyl comprises one to three carbon atoms (e.g., C1-C3 alkyl). In other embodiments, an alkyl comprises one to two carbon atoms (e.g., C1-C2 alkyl).
  • an alkyl comprises one carbon atom (e.g., Ci alkyl). In other embodiments, an alkyl comprises five to fifteen carbon atoms (e.g., C5-C15 alkyl). In other embodiments, an alkyl comprises five to eight carbon atoms (e.g., Cs-Cs alkyl). In other embodiments, an alkyl comprises two to five carbon atoms (e.g., C2-C5 alkyl). In other embodiments, an alkyl comprises three to five carbon atoms (e.g., C3-C5 alkyl).
  • the alkyl group is selected from methyl, ethyl, 1 -propyl (//-propyl), 1 -methylethyl (Ao-propyl), 1 -butyl (//-butyl), 1 -methylpropyl (secbutyl), 2-methylpropyl (Ao-butyl), 1,1 -dimethylethyl (tert-butyl), 1 -pentyl (//-pentyl).
  • the alkyl is attached to the rest of the molecule by a single bond.
  • alkyl groups are each independently substituted or unsubstituted.
  • alkyl includes a specific and explicit recitation of an unsaturated “alkyl” group.
  • an alkyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR X , -SR X , -OC(O)-R X , -N(R X ) 2 , -C(O)R X , -C(O)OR X , -C(O)N(R X ) 2 , - N(R X )C(O)OR X , -OC(O)-N(R X ) 2 , -N(R X )C(O)R X , -N(R x )S(O) t
  • an “alkylene” group refers to a divalent alkyl radical. Any of the above mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl. In some embodiments, an alkylene is a Ci-Cealkylene. In other embodiments, an alkylene is a Ci-C4alkylene.
  • Typical alkylene groups include, but are not limited to, -CH 2 -, -CH(CH3)-, - C(CH 3 ) 2 -, -CH 2 CH 2 -, -CH 2 CH(CH 3 )-, -CH 2 C(CH 3 ) 2 -, -CH 2 CH 2 CH 2 -, -CH 2 CH 2 CH 2 CH 2 -, and the like.
  • an alkylene chain is optionally substituted as described for alkyl groups herein.
  • alkenyl refers to a type of alkyl group in which at least one carbon-carbon double bond is present.
  • R is H or an alkyl.
  • alkynyl refers to a type of alkyl group in which at least one carbon-carbon triple bond is present.
  • R is H or an alkyl.
  • An “alkoxy” group refers to a (alkyl)O- group, where alkyl is as defined herein.
  • alkylamine refers to -NH(alkyl), or -N(alkyl) 2 .
  • aromatic refers to a planar ring having a delocalized ⁇ -electron system containing 4n+2 % electrons, where n is an integer.
  • aromatic includes both carbocyclic aryl (“aryl”, e.g., phenyl) and heterocyclic aryl (or “heteroaryl” or “heteroaromatic”) groups (e.g., pyridine).
  • aryl e.g., phenyl
  • heterocyclic aryl or “heteroaryl” or “heteroaromatic” groups
  • pyridine e.g., pyridine
  • the term includes monocyclic or fused-ring polycyclic (z.e., rings which share adjacent pairs of carbon atoms) groups.
  • carbocyclic or “carbocycle” refers to a ring or ring system where the atoms forming the backbone of the ring are all carbon atoms. The term thus distinguishes carbocyclic from “heterocyclic” rings or “heterocycles” in which the ring backbone contains at least one atom which is different from carbon. In some embodiments, at least one of the two rings of a bicyclic carbocycle is aromatic. In some embodiments, both rings of a bicyclic carbocycle are aromatic. In certain embodiments, a carbocyclyl comprises three to ten carbon atoms. In other embodiments, a carbocyclyl comprises five to seven carbon atoms.
  • Carbocyclyl or cycloalkyl is saturated (z.e., containing single C-C bonds only) or unsaturated (z.e., containing one or more double bonds or triple bonds).
  • saturated cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • An unsaturated carbocyclyl is also referred to as "cycloalkenyl.”
  • monocyclic cycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
  • Polycyclic carbocyclyl radicals include, for example, adamantyl, norbomyl (i.e., bicyclo[2.2.1]heptanyl), norbomenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
  • carbocyclyl is meant to include carbocyclyl radicals that are optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R y -OR X , -R y -OC(O)-R x , -R y -OC(O)-OR x , -R y - OC(O)-N(
  • aryl refers to an aromatic ring wherein each of the atoms forming the ring is a carbon atom.
  • the aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon from five to eighteen carbon atoms, where at least one of the rings in the ring system is fully unsaturated, z.e., it contains a cyclic, delocalized (4n+2) %- electron system in accordance with the Hiickel theory.
  • the ring system from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin and naphthalene.
  • aryl or the prefix “ar-” (such as in “aralkyl”) is meant to include aryl radicals optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R y -OR X , -R y -OC(O)-R x , - R y -OC(O)-OR x , -R y -OC(O)-N(R
  • Aralkyl refers to a radical of the formula -R z -aryl where R z is an alkylene chain as defined above, for example, methylene, ethylene, and the like.
  • the alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain.
  • the aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.
  • cycloalkyl refers to a monocyclic or polycyclic aliphatic, non-aromatic radical, wherein each of the atoms forming the ring (i.e., skeletal atoms) is a carbon atom.
  • cycloalkyls are spirocyclic or bridged compounds.
  • cycloalkyls are optionally fused with an aromatic ring, and the point of attachment is at a carbon that is not an aromatic ring carbon atom.
  • Cycloalkyl groups include groups having from 3 to 10 ring atoms.
  • cycloalkyl groups are selected from among cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, spiro[2.2]pentyl, norbomyl and bicycle[l.l.l]pentyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, adamantyl, norbornyl, and decalinyl.
  • a cycloalkyl is a Cs-Cecycloalky
  • halo or, alternatively, “halogen” or “halide” means fluoro, chloro, bromo or iodo. In some embodiments, halo is fluoro, chloro, or bromo. In some embodiments, halo is fluoro or chloro.
  • fluoroalkyl refers to an alkyl in which one or more hydrogen atoms are replaced by a fluorine atom, such as, for example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, l-fluoromethyl-2-fluoroethyl, and the like.
  • the alkyl part of the fluoroalkyl radical is optionally substituted as defined above for an alkyl group.
  • a fluoroalkyl is a Ci-Cefhioroalkyl.
  • heteroalkyl refers to an alkyl group as defined above in which one or more skeletal carbon atoms of the alkyl are substituted with a heteroatom (with the appropriate number of substituents or valencies - for example, -CH2- may be replaced with -NH-, -S-, or -O-).
  • each substituted carbon atom is independently substituted with a heteroatom, such as wherein the carbon is substituted with a nitrogen, oxygen, selenium, or other suitable heteroatom.
  • each substituted carbon atom is independently substituted for an oxygen, nitrogen (e.g.
  • a heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. In some embodiments, a heteroalkyl is attached to the rest of the molecule at a heteroatom of the heteroalkyl. In some embodiments, a heteroalkyl is a Ci-Cis heteroalkyl. In some embodiments, a heteroalkyl is a C1-C12 heteroalkyl.
  • a heteroalkyl is a Ci-Ce heteroalkyl. In some embodiments, a heteroalkyl is a C1-C4 heteroalkyl. In some embodiments, a heteroalkyl is or includes one or more cyclic group(s). In some embodiments, heteroalkyl includes alkylamino, alkylaminoalkyl, aminoalkyl, heterocyclyl, heterocycloalkyl, heterocycloalkyl, and heterocycloalkylalkyl, as defined herein. Unless stated otherwise specifically in the specification, a heteroalkyl group is optionally substituted as defined above for an alkyl group. In one embodiment, a heteroalkyl is a Ci-Ceheteroalkyl.
  • Heteroalkylene refers to a divalent heteroalkyl group defined above which links one part of the molecule to another part of the molecule. Unless stated specifically otherwise, a heteroalkylene is optionally substituted, as defined above for an alkyl group.
  • heterocyclyl generally refer to heteroaromatic rings (also known as heteroaryls) and heterocycloalkyl rings (also known as heteroalicyclic groups) containing one to four heteroatoms in the ring(s), where each heteroatom in the ring(s) is selected from O, S and N, wherein each heterocyclic group has from 3 to 10 atoms in its ring system, and with the proviso that any ring does not contain two adjacent O or S atoms.
  • the heterocyclyl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which optionally includes fused or bridged ring systems.
  • the heteroatoms in the heterocyclyl radical are optionally oxidized.
  • One or more nitrogen atoms, if present, are optionally quaternized.
  • the heterocyclyl radical is partially or fully saturated.
  • the heterocyclyl radical is saturated (z.e., containing single C-C bonds only) or unsaturated (e.g., containing one or more double bonds or triple bonds in the ring system).
  • the heterocyclyl radical is saturated.
  • the heterocyclyl radical is saturated and substituted.
  • the heterocyclyl radical is unsaturated.
  • the heterocyclyl is attached to the rest of the molecule through any atom of the ring(s).
  • Non-aromatic heterocyclic groups also known as heterocycloalkyls
  • aromatic heterocyclic groups include rings having 5 to 10 atoms in its ring system.
  • the heterocyclic groups include benzo-fused ring systems.
  • non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, oxazolidinonyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, pyrrolin-2-yl, pyrrolin-3-yl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl,
  • aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinox
  • a group derived from pyrrole includes both pyrrol-l-yl (TV-attached) or pyrrol-3-yl (C-attached).
  • a group derived from imidazole includes imidazol-l-yl or imidazol-3-yl (both TV-attached) or imidazol-2-yl, imidazol-4-yl or imidazol-5-yl (all C-attached).
  • the heterocyclic groups include benzo-fused ring systems.
  • at least one of the two rings of a bicyclic heterocycle is aromatic.
  • both rings of a bicyclic heterocycle are aromatic.
  • heterocyclyl is meant to include heterocyclyl radicals as defined above that are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R y -0R x , -R y -0C(0)-R x , -R y -0C(0)-0R x , -R y -0C(0)-N(R
  • Heterocyclylalkyl refers to a radical of the formula -R z -heterocyclyl where R z is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom.
  • the alkylene chain of the heterocyclylalkyl radical is optionally substituted as defined above for an alkylene chain.
  • the heterocyclyl part of the heterocyclylalkyl radical is optionally substituted as defined above for a heterocyclyl group.
  • Heterocyclylalkoxy refers to a radical bonded through an oxygen atom of the formula - O-R z -heterocyclyl where R z is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom.
  • the alkylene chain of the heterocyclylalkoxy radical is optionally substituted as defined above for an alkylene chain.
  • the heterocyclyl part of the heterocyclylalkoxy radical is optionally substituted as defined above for a heterocyclyl group.
  • heteroaryl or, alternatively, “heteroaromatic” refers to an aryl group that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur.
  • heteroaryl groups include monocyclic heteroaryls and bicyclcic heteroaryls.
  • Monocyclic heteroaryls include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl, and furazanyl.
  • Bicyclic heteroaryls include indolizine, indole, benzofuran, benzothiophene, indazole, benzimidazole, purine, quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine.
  • a heteroaryl contains 0-4 N atoms in the ring.
  • a heteroaryl contains 1-4 N atoms in the ring.
  • a heteroaryl contains 0-4 N atoms, 0-1 0 atoms, and 0-1 S atoms in the ring.
  • a heteroaryl contains 1-4 N atoms, 0-1 0 atoms, and 0-1 S atoms in the ring.
  • heteroaryl is a Ci-Cgheteroaryl.
  • monocyclic heteroaryl is a Ci-Csheteroaryl.
  • monocyclic heteroaryl is a 5-membered or 6-membered heteroaryl.
  • bicyclic heteroaryl is a Ce-Cgheteroaryl.
  • heteroaryl is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R y -OR X , -R y -OC(O)-R x , -R y -OC(O)-OR x
  • Heteroarylalkyl refers to a radical of the formula -R z -heteroaryl, where R z is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom. The alkylene chain of the heteroarylalkyl radical is optionally substituted as defined above for an alkylene chain. The heteroaryl part of the heteroarylalkyl radical is optionally substituted as defined above for a heteroaryl group.
  • Heteroarylalkoxy refers to a radical bonded through an oxygen atom of the formula -O- R z -heteroaryl, where R z is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom.
  • the alkylene chain of the heteroarylalkoxy radical is optionally substituted as defined above for an alkylene chain.
  • the heteroaryl part of the heteroaryl alkoxy radical is optionally substituted as defined above for a heteroaryl group.
  • heterocycloalkyl or “heteroalicyclic” group refers to a cycloalkyl group that includes at least one heteroatom selected from nitrogen, oxygen and sulfur. In some embodiments, a heterocycloalkyl is fused with an aryl or heteroaryl.
  • the heterocycloalkyl is oxazolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidin-2-onyl, pyrrolidine-2, 5-dithionyl, pyrrolidine-2, 5-dionyl, pyrrolidinonyl, imidazolidinyl, imidazolidin-2- onyl, or thiazolidin-2-onyl.
  • heteroalicyclic also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides.
  • a heterocycloalkyl is a C2-Cioheterocycloalkyl.
  • a heterocycloalkyl is a C4-Cioheterocycloalkyl.
  • a heterocycloalkyl contains 0-2 N atoms in the ring.
  • a heterocycloalkyl contains 0-2 N atoms, 0-2 O atoms and 0-1 S atoms in the ring.
  • bond refers to a chemical bond between two atoms, or two moi eties when the atoms joined by the bond are considered to be part of larger substructure.
  • bond when a group described herein is a bond, the referenced group is absent thereby allowing a bond to be formed between the remaining identified groups.
  • moiety refers to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule. [0061] In general, optionally substituted groups are each independently substituted or unsubstituted. Each recitation of an optionally substituted group provided herein, unless otherwise stated, includes an independent and explicit recitation of both an unsubstituted group and a substituted group (e.g., substituted in certain embodiments, and unsubstituted in certain other embodiments).
  • a substituted group provided herein is substituted by one or more substituent, each substituent being independently selected from the group consisting of: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR X , -SIU, - OC(O)-R X , -N(R X ) 2 , -C(O)R X , -C(O)OR X , -C(O)N(R X ) 2 , -N(R X )C(O)OR X , -OC(O)-N(R X ) 2 , - N(R X )C(O)R X , -N(R x )S(O)tR x (where t is 1 or 2), -S(O)tOR x (where t is
  • optional substituents are independently selected from halogen, - CN, -NH 2 , -OH, -NH(CH 3 ), -N(CH 3 ) 2 , -CH 3 , -CH 2 CH 3 , -CF 3 , -OCH 3 , and -OCF 3 .
  • substituted groups are substituted with one or two of the preceding groups.
  • modulate means to interact with a target either directly or indirectly so as to alter the activity of the target, including, by way of example only, to enhance the activity of the target, to inhibit the activity of the target, to limit the activity of the target, or to extend the activity of the target.
  • modulate means to interact with a target either directly or indirectly so as to decrease or inhibit receptor activity.
  • modulation is an increase or decrease in the amount, quality, or effect of a particular activity, function or molecule.
  • agonists, partial agonists, antagonists, and allosteric modulators are modulators of the receptor.
  • allosteric modulators e.g., a positive allosteric modulator
  • a G protein-coupled receptor e.g., 5HT 2 A
  • modulator refers to a molecule that interacts with a target either directly or indirectly.
  • the interactions include, but are not limited to, the interactions of an agonist, partial agonist, an inverse agonist, antagonist, or combinations thereof.
  • a modulator is an antagonist.
  • Receptor antagonists are inhibitors of receptor activity. Antagonists mimic ligands that bind to a receptor and prevent receptor activation by a natural ligand. Preventing activation may have many effects. If a natural agonist binding to a receptor leads to an increase in cellular function, an antagonist that binds and blocks this receptor decreases the function of the receptor.
  • Agonism generally refers to the activation of a receptor or enzyme by a modulator, or agonist, to produce a biological response.
  • agonist generally refers to a modulator that binds to a receptor or enzyme and activates the receptor to produce a biological response.
  • a “5HT 2 A agonist” can be used to refer to a compound that exhibits an ECso with respect to 5HT 2 A activity of no more than about 100 pM.
  • the term “agonist” includes full agonists or partial agonists.
  • Full agonist refers to a modulator that binds to and activates a receptor with the maximum response that an agonist can elicit at the receptor.
  • Partial agonist refers to a modulator that binds to and activates a given receptor, but has partial efficacy, that is, less than the maximal response, at the receptor relative to a full agonist.
  • positive allosteric modulator generally refers to a modulator that binds to a site distinct from the orthosteric binding site and enhances or amplifies the effect of an agonist.
  • anti-antagonism generally refers to the inactivation of a receptor or enzyme by a modulator, or antagonist.
  • Antagonism of a receptor for example, is when a molecule binds to the receptor and blocks function of the receptor.
  • antagonist generally refers to a modulator that binds to a receptor or enzyme and blocks a biological response.
  • An antagonist may have no activity in the absence of an agonist or inverse agonist but can block the activity of either, causing no change in the biological response.
  • administer refers to the methods that may be used to enable delivery of compounds or compositions to the desired site of biological action. These methods include, but are not limited to oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular or infusion), topical and rectal administration. Those of skill in the art are familiar with administration techniques that can be employed with the compounds and methods described herein. In some embodiments, the compounds and compositions described herein are administered orally.
  • an “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of an agent or a compound being administered, which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result includes reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
  • an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms.
  • An appropriate “effective” amount in any individual case is optionally determined using techniques, such as a dose escalation study.
  • the terms “enhance” or “enhancing,” as used herein, means to increase or prolong either in potency or duration a desired effect.
  • the term “enhancing” refers to the ability to increase or prolong, either in potency or duration, the effect of other therapeutic agents on a system.
  • An “enhancing-effective amount,” as used herein, refers to an amount adequate to enhance the effect of another therapeutic agent in a desired system.
  • kit and “article of manufacture” are used as synonyms.
  • the term “subject” or “patient” encompasses mammals.
  • mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
  • the mammal is a human.
  • treat include alleviating, abating or ameliorating at least one symptom of a disease or condition, preventing additional symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically.
  • pharmaceutically acceptable generally refers a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively nontoxic, i.e., the material is administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
  • pharmaceutically acceptable salt generally refers to a form of a therapeutically active agent that consists of a cationic form of the therapeutically active agent in combination with a suitable anion, or in alternative embodiments, an anionic form of the therapeutically active agent in combination with a suitable cation.
  • Handbook of Pharmaceutical Salts Properties, Selection and Use. International Union of Pure and Applied Chemistry, Wiley - VCH 2002. S.M. Berge, L.D. Bighley, D.C. Monkhouse, J. Pharm. Sci. 1977, 66, 1-19. P. H. Stahl and C. G.
  • Pharmaceutical salts typically are more soluble and more rapidly soluble in stomach and intestinal juices than non-ionic species and so are useful in solid dosage forms. Furthermore, because their solubility often is a function of pH, selective dissolution in one or another part of the digestive tract is possible and this capability can be manipulated as one aspect of delayed and sustained release behaviors. Also, because the saltforming molecule can be in equilibrium with a neutral form, passage through biological membranes can be adjusted. Provided herein are non-hallucinogenic compounds that promote neuronal growth and/or improve neuronal structure.
  • 5-HT2A agonism refers to a compound capable of providing 5-HT2A receptor agonism with an ECso of less than 10 pM.
  • compounds provided herein possess comparable affinity for serotonin receptors (e.g., 5HT2A) as compared to their hallucinogenic counterparts.
  • the compounds provided herein have improved physiochemical properties as a result of the loss of a hydrogen bond donor, decreasing total polar surface area and improving central nervous system multiparameter optimization (MPO) scores.
  • MPO central nervous system multiparameter optimization
  • Described herein in some embodiments are non-hallucinogenic compounds that demonstrate similar therapeutic potential as hallucinogenic 5-HT2A agonists.
  • the non-hallucinogenic compounds described herein provide better therapeutic potential than hallucinogenic 5-HT2A agonists for neurological diseases.
  • Neuronal plasticity and changes thereof, have been attributed to many neurological diseases and disorders. For example, during development and in adulthood, changes in dendritic spine number and morphology (e.g., lengths, crossings, density) accompany synapse formation, maintenance and elimination; these changes are thought to establish and remodel connectivity within neuronal circuits. Furthermore, dendritic spine structural plasticity is coordinated with synaptic function and plasticity. For example, spine enlargement is coordinated with long-term potentiation in neuronal circuits, whereas long-term depression is associated with spine shrinkage.
  • dendritic spine number and morphology e.g., lengths, crossings, density
  • dendritic spine structural plasticity is coordinated with synaptic function and plasticity. For example, spine enlargement is coordinated with long-term potentiation in neuronal circuits, whereas long-term depression is associated with spine shrinkage.
  • dendritic spines undergo experience-dependent morphological changes in live animals, and even subtle changes in dendritic spines can affect synaptic function, synaptic plasticity, and patterns of connectivity in neuronal circuits.
  • disease-specific disruptions in dendritic spine shape, size, and/or number accompany neurological diseases and disorders, such as, for example, neurodegenerative (e.g., Alzheimer’s disease or Parkinson’s disease) and neuropsychiatric (e.g., depression or schizophrenia) diseases and disorders, suggesting that dendritic spines may serve as a common substrate in diseases that involve deficits in information processing.
  • neurodegenerative e.g., Alzheimer’s disease or Parkinson’s disease
  • neuropsychiatric e.g., depression or schizophrenia
  • disclosed herein are methods of treating neurological diseases and disorders with a compound of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), or any compound covered by such formulae, for example any compound described in Table 1, or a pharmaceutically acceptable salt or solvate thereof.
  • a neurological disease or disorder is a disease or disorder of the central nervous system (CNS) (e.g., brain, spine, and/or nerves) of an individual.
  • CNS central nervous system
  • Types of neurological diseases and disorders include, but are not limited to, neurodegenerative diseases (such as Alzheimer’s disease, Parkinson’s disease, and dementia), headaches (e.g., migraines), brain injury (e.g., stroke or traumatic brain injury), brain cancer, an anxiety disorder (e.g., post-traumatic stress disorder (PTSD) or obsessive-compulsive disorder (OCD)), a mood disorder (e.g., suicidal ideation, depression, or bipolar disorder), a psychotic disorder (e.g., schizophrenia or substance-induced psychotic disorder), a personality disorder, an eating disorder (e.g., binge eating disorder), a sleep disorder, a sexuality disorder, an impulse control disorder (e.g., gambling, compulsive sexuality, or kleptomania), a substance use disorder (e.g., alcohol dependence, opioid addiction, or cocaine addiction), a dissociative disorder (e.g., epilepsy, amnesia, or dissociative identity disorder), a cognitive disorder
  • Neurodegenerative diseases or disorders include, but are not limited to, Alzheimer’s disease (AD), Parkinson’s disease (PD), prion disease, frontotemporal dementia, motor neuron disease (MND), Huntington’s disease (HD), Lewy Body dementia (LBD), and the like.
  • AD Alzheimer’s disease
  • PD Parkinson’s disease
  • MND motor neuron disease
  • HD Huntington’s disease
  • LBD Lewy Body dementia
  • Substance use disorders include, but are not limited to, substance abuse, addiction and dependence, such as addiction or dependence to alcohol, opioids (e.g., heroin, oxycodone, and hydrocodone), cocaine, amphetamines (e.g., methamphetamine), nicotine, cannabinoids (e.g., tetrahydrocannabinol (THC)), caffeine, phencyclidine, paint thinner, glue, steroids (e.g., anabolic steroids), barbiturates (e.g., phenobarbital), methadone, benzodiazepines (e.g., diazepam), and the like.
  • opioids e.g., heroin, oxycodone, and hydrocodone
  • cocaine e.g., heroin, oxycodone, and hydrocodone
  • amphetamines e.g., methamphetamine
  • nicotine e.g., cannabinoids (e.g., tetrahydr
  • Impulse control disorders include, but are not limited to, gambling, kleptomania, trichotillomania, intermittent explosive disorder, pyromania, skin picking, compulsive buying, Tourette syndrome, compulsive sexual behavior, and the like.
  • Neuropsychiatric disorders include, but are not limited to, seizures (e.g., epilepsy), attention deficit disorders (e.g., ADHD and Autism), eating disorders (e.g., bulimia, anorexia, binge eating disorder, and pica), depression (e.g., clinical depression, persistent depressive disorder, bipolar disorder, postpartum depression, suicidal ideation, major depressive disorder, seasonal depression, and the like), anxiety (e.g., panic attacks, social anxiety disorder, panic disorder, and the like), schizophrenia, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), substance-induced psychotic disorder, substance-induced cognitive impairment, and the like.
  • seizures e.g., epilepsy
  • attention deficit disorders e.g., ADHD and Autism
  • eating disorders e.g., bulimia, anorexia, binge eating disorder, and pica
  • depression e.g., clinical depression, persistent depressive disorder, bipolar disorder, postpartum depression, suicid
  • Brain injury includes, but is not limited to, stroke, traumatic brain injury, dementia pugiliistica, chronic traumatic encephalopathy (CTE), or the like.
  • a compound provided herein e.g., a compound represented by the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), or any compound covered by such formulae, for example any compound described in Table 1), or a pharmaceutically acceptable salt or solvate thereof, improves dendritic spine number and dendritic spine morphology that is lost in neurological diseases and disorders.
  • 5 -HT2A agonism has been correlated with the promotion of neural plasticity (Ly et al., 2018).
  • 5-HT2A antagonists abrogate the neuritogenesis and spinogenesis effects of hallucinogenic compounds with 5-HT2A agonist activity, e.g., DMT, LSD, and DOI.
  • DMT and other psychedelic compounds promote increased dendritic arbor complexity, dendritic spine density, and synaptogenesis through a 5-HT2A-dependent process.
  • pretreating cortical cultures with a 5-HT2A antagonist blocked the ability of 5- MeO-DMT to increase dendritic growth.
  • the psychoplastogenic effects of compounds provided herein are also blocked under these conditions, implicating the 5-HT2A receptor in their mechanism of action.
  • non-hallucinogenic compounds e.g., lisuride and 6- MeO-DMT
  • compounds such as, for example, 6-F-DET, Ketanserin, BOL148, which are non- hallucinogenic in animals (e.g., humans)
  • a compound provided herein prevents binding of 5-HT to 5HT2A.
  • the 5HT2A sensor assay is in an antagonist mode.
  • a compound provided herein prevents binding of 5-HT to 5HT2A and has non- hallucinogenic potential.
  • a compound provided herein prevents binding of 5-HT to 5HT2A and is non-hallucinogenic. In some embodiments, a compound provided herein prevents binding of 5-HT to 5HT2A in antagonist mode has non-hallucinogenic potential. In some embodiments, a compound provided herein prevents binding of 5-HT in antagonist mode is a non- hallucinogenic compound. In some embodiments, a compound provided herein inhibits the response of a sensor assay in antagonist mode has non-hallucinogenic potential. In some embodiments, a compound provided herein inhibits the response of a sensor assay in antagonist mode is a non-hallucinogenic compound.
  • the effect of a compound provided herein on an agonist mode sensor assay suggests the compound is a non-hallucinogenic ligand of the 5-HT2A receptor.
  • the effect of a compound provided herein on an antagonist mode sensor assay suggests the compound is a non-hallucinogenic ligand of the 5-HT2A receptor.
  • effect of a compound provided herein on an agonist mode and an antagonist mode sensor assay together suggest the compound is a non-hallucinogenic ligand of the 5-HT2A receptor.
  • Described in some embodiments are non-hallucinogenic compounds that demonstrate similar therapeutic potential as hallucinogenic 5-HT2A agonists.
  • the non- hallucinogenic compounds described herein provide better therapeutic potential than hallucinogenic 5-HT2A agonists for neurological diseases.
  • the compounds of the present disclosure are 5-HT2A modulators and promote neural plasticity (e.g., cortical structural plasticity).
  • a compound provided herein is a 5-HT2A modulator and promote neural plasticity (e.g., cortical structural plasticity).
  • 5-HT2A modulators e.g., 5-HT2A agonists
  • the brain disorder or other conditions described herein comprise decreased neural plasticity, decreased cortical structural plasticity, decreased 5-HT2A receptor content, decreased dendritic arbor complexity, loss of dendritic spines, decreased dendritic branch content, decreased spinogenesis, decreased neuritogenesis, retraction of neurites, or any combination thereof.
  • a compound provided herein e.g., a compound represented by the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), or any compound covered by such formulae, for example any compound described in Table 1) is neuroplastic (e.g., promotes neural plasticity (e.g., cortical structural plasticity), such as increases neurite outgrowth).
  • neuroplastic e.g., promotes neural plasticity (e.g., cortical structural plasticity), such as increases neurite outgrowth).
  • the compounds provided herein e.g., a compound represented by the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), or any compound covered by such formulae, for example any compound described in Table l)have activity as 5-HT2A modulators.
  • the compounds provided herein elicit a biological response by activating the 5-HT2A receptor (e.g., allosteric modulation or modulation of a biological target that activates the 5-HT2A receptor).
  • the compounds provided herein are selective 5-HT2A modulators and promote neural plasticity (e.g., cortical structural plasticity).
  • promotion of neural plasticity includes, for example, increased dendritic spine growth, increased synthesis of synaptic proteins, strengthened synaptic responses, increased dendritic arbor complexity, increased dendritic branch content, increased spinogenesis, increased neuritogenesis, or any combination thereof.
  • increased neural plasticity includes, for example, increased cortical structural plasticity in the anterior parts of the brain.
  • a compound provided herein e.g., a compound represented by the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), or any compound covered by such formulae, for example any compound described in Table 1) is a 5-HT modulator (e.g., a 5-HT2A agonist or a 5-HT2A antagonist).
  • a 5-HT modulator e.g., a 5-HT2A agonist or a 5-HT2A antagonist
  • a compound provided herein is a 5-HT2A modulator (e.g., a 5- HT 2A agonist or a 5-HT2A antagonist).
  • a compound provided herein is a 5- HT modulator and promotes neural plasticity (e.g., cortical structural plasticity), such as increases neurite outgrowth.
  • a compound provided herein is a 5-HT modulator, promotes neural plasticity (e.g., cortical structural plasticity), and is non-hallucinogenic.
  • a compound provided herein e.g., a compound represented by the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), or any compound covered by such formulae, for example any compound described in Table 1) is a 5-HT2A antagonist.
  • a compound provided herein is a 5-HT2A antagonist and promotes neural plasticity (e.g., cortical structural plasticity), such as increases neurite outgrowth.
  • the compound provided herein is unable to (significantly) provide 5-HT2A agonism and promotes neural plasticity (e.g., cortical structural plasticity), such as increases neurite outgrowth.
  • the compound provided herein is unable to (significantly) provide 5-HT2A agonism, promotes neural plasticity (e.g., cortical structural plasticity), and has a low potential for hallucinogenic activity (e.g., is non-hallucinogenic).
  • a compound provided herein e.g., a compound represented by the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), or any compound covered by such formulae, for example any compound described in Table 1) is a 5-HT2A agonist.
  • a compound provided herein is a 5-HT2A agonist and promotes neural plasticity (e.g., cortical structural plasticity), such as increases neurite outgrowth.
  • the compound provided herein provides (significant) 5-HT2A agonism and promotes neural plasticity (e.g., cortical structural plasticity), such as increases neurite outgrowth.
  • the compound provided herein provides (significant) 5-HT2A agonism, promotes neural plasticity (e.g., cortical structural plasticity), and has a low potential for hallucinogenic activity (e.g., is non- hallucinogenic).
  • the 5-HT2A modulators e.g., 5-HT2A agonists
  • non-hallucinogenic 5-HT2A modulators e.g., 5-HT2A agonists
  • the hallucinogenic potential of the compounds described herein is assessed in vitro.
  • the hallucinogenic potential assessed in vitro of the compounds described herein is compared to the hallucinogenic potential assessed in vitro of hallucinogenic homologs.
  • non-hallucinogenic 5-HT2A modulators e.g., 5-HT2A agonists
  • the neurological diseases comprise decreased neural plasticity, decreased cortical structural plasticity, decreased 5-HT2A receptor content, decreased dendritic arbor complexity, loss of dendritic spines, decreased dendritic branch content, decreased spinogenesis, decreased neuritogenesis, retraction of neurites, or any combination thereof.
  • non-hallucinogenic 5-HT2A modulators are used for increasing neuronal plasticity.
  • non-hallucinogenic 5-HT2A modulators e.g., 5-HT2A agonists
  • non-hallucinogenic 5-HT2A modulators e.g., 5-HT2A agonists
  • the experiment or assay to determine increased neuronal plasticity of any compound of the present disclosure is a phenotypic assay, a dendritogenesis assay, a spinogenesis assay, a synaptogenesis assay, a Sholl analysis, a concentration-response experiment, a 5-HT2A agonist assay, a 5-HT2A antagonist assay, a 5-HT2A binding assay, or a 5-HT2A blocking experiment (e.g., ketanserin blocking experiments).
  • the experiment or assay to determine the hallucinogenic potential of a compound of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4) provided herein is a mouse head-twitch response (HTR) assay.
  • HTR mouse head-twitch response
  • a compound described herein, including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof is a pyrrolidine psychoplastogen.
  • a compound described herein, including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof is a fused pyrrolidine psychoplastogen.
  • a compound described herein, including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof is a psychoplastogen comprising an indole moiety.
  • a compound described herein, including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof is a psychoplastogen comprising a l,2,3,4,5,6-hexahydroazepino[4,5-b]indole moiety.
  • a compound described herein, including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof is a psychoplastogen comprising a 2,3,4,5-tetrahydro-lH-[l,4]diazepino[l,7-a]indole moiety.
  • a compound described herein including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof, is a psychoplastogen comprising a l,2,3,5,6,l l,12,12a-octahydropyrrolo[l',2': l,2]azepino[4,5-b]indole moiety.
  • a compound described herein including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof, is a psychoplastogen comprising a 2,3,5,6,13,13a-hexahydro-lH-pyrrolo[l',2':4,5][l,4]diazepino[l,7-a]indole moiety.
  • a compound described herein including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof, is a psychoplastogen comprising a l,2,3,5,6,7,12,12a-octahydropyrrolo[l',2': l,7]azepino[4,5-b]indole moiety.
  • a compound described herein including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof, is a psychoplastogen comprising a 2,3,5,6,13,13a-hexahydro-lH-pyrrolo[2',l':3,4][l,4]diazepino[l,7-a]indole moiety.
  • a compound described herein, including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof is a psychoplastogen comprising a 2,3,4,5-tetrahydro-lH-pyrido[4,3-b]indole moiety.
  • a compound described herein, including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof is a psychoplastogen comprising a 2,3,5,10,11,1 la-hexahydro-lH-indolizino[7,6-b]indole moiety.
  • a compound described herein including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof, is a psychoplastogen comprising a 2, 3, 5, 6, 7,1 lc-hexahydro-lH-indolizino[7,8-b]indole moiety.
  • a compound described herein, including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof is a psychoplastogen comprising a benzofuran moiety.
  • a compound described herein, including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof is a psychoplastogen comprising a 1,2, 3, 4- tetrahydrobenzofuro[3,2-c]pyridine moiety.
  • a compound described herein, including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites and solvates thereof is a psychoplastogen comprising a 1, 2,3,4- tetrahydrobenzofuro[3,2-c]pyridine moiety fused to a pyrrolidine moiety.
  • a compound described herein, including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites and solvates thereof is a psychoplastogen comprising a 1,2, 3, 5,11,1 la-hexahydrobenzofuro[3,2-f]indolizine moiety.
  • a compound described herein including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites and solvates thereof, is a psychoplastogen comprising a 1,2,3,5,6,11c- hexahydrobenzofuro[2,3-g]indolizine moiety.
  • a compound described herein including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof, is a psychoplastogen comprising a benzothiophene moiety or an oxidized (e.g., sulfoxide, sulfone) derivative thereof.
  • a compound described herein including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof, is a psychoplastogen comprising a l,2,3,4-tetrahydrobenzo[4,5]thieno[3,2- c]pyridine moiety or an oxidized (e.g., sulfoxide, sulfone) derivative thereof.
  • a compound described herein including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof, is a psychoplastogen comprising a l,2,3,4-tetrahydrobenzo[4,5]thieno[3,2-c]pyridine or an oxidized (e.g., sulfoxide, sulfone) derivative thereof, fused to a pyrrolidine moiety.
  • a compound described herein including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof, is a psychoplastogen comprising a 1,2, 3, 5,11,1 la- hexahydrobenzo[4,5]thieno[3,2-f]indolizine moiety, or an oxidized (e.g., sulfoxide, sulfone) derivative thereof.
  • a compound described herein including pharmaceutically acceptable salts, prodrugs, isotopically enriched variants, active metabolites, and solvates thereof, is a psychoplastogen comprising a l,2,3,5,6,l lc-hexahydrobenzo[4,5]thieno[2,3- g]indolizine moiety, or an oxidized (e.g., sulfoxide, sulfone) derivative thereof.
  • A, B, and C are each independently NR 7 , CHR 6a , or CHR 6b , wherein one of A, B, and C is NR 7 and the remaining two of A, B, and C are CHR 6a or CHR 6b ; each of R 1 , R 2 , R 3 , R 4 , and R 5 is independently hydrogen, halogen, -OR a , -SR a , -NR b R c , - CN, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, heteroaryl, arylalkyl, cycl
  • R b and R c are each independently hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci- ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, arylalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or
  • R b and R c are taken together with the nitrogen to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 7 and R 6a are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 7 and R 6b are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 6a and R 6b are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring or an optionally substituted cycloalkyl ring.
  • each of R 1 , R 2 , R 3 , R 4 , and R 5 is independently hydrogen, halogen, -OR a , -SR a , -NR b R c , - CN, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R; or any of R 1 and R 2 , R 2 and R 3 , or R 3 and R 4 are taken together with the carbon
  • R 6a and R 6b are each independently hydrogen, halogen, -OR a , -SR a , -NR b R c , -CN, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R; or R 7 is taken together with R 6a or R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R; or R 6a and R 6b are taken together with the intervening atoms to which
  • R -R b and R c are each independently hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci- ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, arylalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R; or
  • [00112] in some embodiments of Formula (I), represents a single bond. In some embodiments, represents a double bond.
  • A is NR 7
  • B is CHR 6a
  • C is CHR 6b .
  • R 7 is Ci-ealkyl optionally substituted with one or more R.
  • R 7 is methyl.
  • R 7 is taken together with R 6a or R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R.
  • R 7 is taken together with R 6a or R 6b and the intervening atoms to which they are attached to form an optionally substituted pyrrolidine, wherein the pyrrolidine is optionally substituted with one or more R. In some embodiments, wherein R 7 is taken together with R 6a or R 6b and the intervening atoms to which they are attached to form a pyrrolidine. In some embodiments, R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R.
  • R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted pyrrolidine, wherein pyrrolidine is optionally substituted with one or more R. In some embodiments, R 7 is taken together with R 6a and the intervening atoms to which they are attached to form a pyrrolidine.
  • R 6b is hydrogen or Ci-ealkyl optionally substituted with one or more R. In some embodiments, R 6b is hydrogen. In some embodiments, R 6b is methyl.
  • A is CHR 6a
  • B is NR 7
  • C is CHR 6b
  • R 7 is Ci-ealkyl optionally substituted with one or more R.
  • R 7 is methyl.
  • R 7 is taken together with R 6a or R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R.
  • R 7 is taken together with R 6a or R 6b and the intervening atoms to which they are attached to form an optionally substituted pyrrolidine, wherein the pyrrolidine is optionally substituted with one or more R. In some embodiments, wherein R 7 is taken together with R 6a or R 6b and the intervening atoms to which they are attached to form a pyrrolidine. In some embodiments, R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R.
  • R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted pyrrolidine, wherein pyrrolidine is optionally substituted with one or more R. In some embodiments, R 7 is taken together with R 6a and the intervening atoms to which they are attached to form a pyrrolidine.
  • R 6b is hydrogen or Ci-ealkyl optionally substituted with one or more R. In some embodiments, R 6b is hydrogen. In some embodiments, R 6b is methyl.
  • R 7 is taken together with R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R. In some embodiments, R 7 is taken together with R 6b and the intervening atoms to which they are attached to form an optionally substituted pyrrolidine, wherein the pyrrolidine is optionally substituted with one or more R. In some embodiments, R 7 is taken together with R 6b and the intervening atoms to which they are attached to form a pyrrolidine. In some embodiments, R 6a is hydrogen or Ci-ealkyl optionally substituted with one or more R. In some embodiments, R 6a is hydrogen. In some embodiments, R 6a is methyl.
  • R 7 is taken together with R 6a or R 6b and the intervening atoms to which they are attached to form an optionally substituted pyrrolidine, wherein the pyrrolidine is optionally substituted with one or more R. In some embodiments, wherein R 7 is taken together with R 6a or R 6b and the intervening atoms to which they are attached to form a pyrrolidine. In some embodiments, R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R.
  • R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted pyrrolidine, wherein pyrrolidine is optionally substituted with one or more R. In some embodiments, R 7 is taken together with R 6a and the intervening atoms to which they are attached to form a pyrrolidine.
  • R 6b is hydrogen or Ci-ealkyl optionally substituted with one or more R. In some embodiments, R 6b is hydrogen. In some embodiments, R 6b is methyl.
  • R 7 is taken together with R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R. In some embodiments, R 7 is taken together with R 6b and the intervening atoms to which they are attached to form an optionally substituted pyrrolidine, wherein the pyrrolidine is optionally substituted with one or more R. In some embodiments, R 7 is taken together with R 6b and the intervening atoms to which they are attached to form a pyrrolidine. In some embodiments, R 6a is hydrogen or Ci-ealkyl optionally substituted with one or more R. In some embodiments, R 6a is hydrogen. In some embodiments, R 6a is methyl.
  • A is CHR 6a
  • B is NR 7
  • C is CHR 6b
  • R 6a is hydrogen
  • R 7 is taken together with R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R
  • the compound of Formula (I) has the structure of Formula (IA):
  • m is 0, 1, or 2.
  • m is 1, 2 or 3.
  • m is 0 of 1.
  • m is 1 or 2.
  • m is 2 or 3.
  • m is 0.
  • m is 1.
  • m is 2.
  • m is 3.
  • n is 0-5.
  • n is 0-3. In some embodiments, n is 0-1. In some embodiments, n is 1-5. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. [00118] In some embodiments of Formula (IA), n is 0, m is 1, and the compound of Formula (IA) has the structure of Formula (IA-1):
  • Formula (IA-1) represents a single bond. In some embodiments, represents a double bond.
  • A is CHR 6a
  • B is NR 7
  • C is CHR 6b
  • R 6b is hydrogen
  • R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R
  • the compound of Formula (I) has the structure of Formula (IB):
  • m is 0, 1, or 2.
  • m is 1, 2 or 3.
  • m is 0 of 1.
  • m is 1 or 2.
  • m is 2 or 3.
  • m is 0.
  • m is 1.
  • m is 2.
  • m is 3.
  • n is 0-5.
  • n is 0-3. In some embodiments, n is 0-1. In some embodiments, n is 1-5. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7.
  • n is 0, m is 1, and the compound of Formula (IB) has the structure of Formula (IB-1):
  • Formula (IB-1) represents a single bond. In some embodiments, represents a double bond.
  • each of R 1 , R 2 , R 3 , R 4 and R 5 is independently hydrogen, halogen, -OR a , - NR b R c , - CN, Ci-ealkyl, or Ci-ehaloalkyl.
  • each of R 1 , R 2 , R 3 , R 4 and R 5 is independently hydrogen, fluoro, chloro, -OR a , - NH2, -NHMe, -N(Me)2, -CN, Ci-ealkyl, or Ci- ehaloalkyl.
  • R a is Ci-ealkyl, Ci-ehaloalkyl, or arylalkyl. In some embodiments, wherein R a is Ci-ealkyl, Ci-ehaloalkyl, or benzyl. In some embodiments, at least one of R 1 , R 2 , R 3 , R 4 and R 5 is halogen. In some embodiments, at least one of R 1 , R 2 , R 3 , R 4 and R 5 is fluoro. In some embodiments, at least one of R 1 , R 2 , R 3 , R 4 and R 5 is fluoro, and the rest of R 1 , R 2 , R 3 , R 4 and R 5 is hydrogen.
  • At least two of R 1 , R 2 , R 3 , R 4 and R 5 is fluoro, and the rest of R 1 , R 2 , R 3 , R 4 and R 5 is hydrogen.
  • at least one of R 1 , R 2 , R 3 , R 4 and R 5 is Ci-ehaloalkyl.
  • at least one of R 1 , R 2 , R 3 , R 4 and R 5 is -CF3, - CHF2, or - CH2F.
  • at least one of R 1 , R 2 , R 3 , R 4 and R 5 is OR a , and wherein R a is Ci-ehaloalkyl.
  • At least one of R 1 , R 2 , R 3 , R 4 and R 5 is OR a , and wherein R a is -CF3, -CHF2, or - CH2F. In some embodiments, at least one of R 1 , R 2 , R 3 , R 4 and R 5 is OR a , and wherein R a is arylalkyl. In some embodiments, at least one of R 1 , R 2 , R 3 , R 4 and R 5 is OR a , and wherein R a is benzyl. In some embodiments, at least one of R 1 , R 2 , R 3 , R 4 and R 5 is OR a , and wherein R a is Ci-ealkyl.
  • At least one of R 1 , R 2 , R 3 , R 4 and R 5 is OR a , and wherein R a is methyl, ethyl, isopropyl, or tert-butyl. In some embodiments, at least one of R 1 , R 2 , R 3 , R 4 and R 5 is benzyloxy, methoxy, fluoro, trifluoromethyl, or trifluorom ethoxy. In some embodiments, each of R 1 , R 2 , R 3 , R 4 and R 5 is hydrogen.
  • R 1 is hydrogen, halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 2 , R 3 , R 4 , and R 5 are each hydrogen.
  • R 1 is halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 2 , R 3 , R 4 , and R 5 are each hydrogen.
  • R 1 is benzyloxy, methoxy, fluoro, trifluoromethyl, or trifluoromethoxy, and R 2 , R 3 , R 4 , and R 5 are each hydrogen.
  • R 2 is hydrogen, halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 1 , R 3 , R 4 , and R 5 are each hydrogen.
  • R 2 is halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 1 , R 3 , R 4 , and R 5 are each hydrogen.
  • R 2 is benzyloxy, methoxy, fluoro, trifluoromethyl, or trifluoromethoxy, and R 1 , R 3 , R 4 , and R 5 are each hydrogen.
  • R 3 is hydrogen, halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 1 , R 2 , R 4 , and R 5 are each hydrogen.
  • R 3 is halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 1 , R 2 , R 4 , and R 5 are each hydrogen.
  • R 3 is benzyloxy, methoxy, fluoro, trifluoromethyl, or trifluoromethoxy, and R 1 , R 2 , R 4 , and R 5 are each hydrogen.
  • R 4 is hydrogen, halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 1 , R 2 , R 3 , and R 5 are each hydrogen.
  • R 4 is halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 1 , R 2 , R 3 , and R 5 are each hydrogen.
  • R 4 is benzyloxy, methoxy, fluoro, trifluoromethyl, or trifluoromethoxy, and R 1 , R 2 , R 3 , and R 5 are each hydrogen.
  • R 5 is hydrogen, halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 1 , R 2 , R 3 , and R 4 are each hydrogen.
  • R 5 is halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 1 , R 2 , R 3 , and R 4 are each hydrogen.
  • R 5 is benzyloxy, methoxy, fluoro, trifluoromethyl, or trifluoromethoxy, and R 1 , R 2 , R 3 , and R 4 are each hydrogen.
  • R 1 and R 2 are each independently halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 3 , R 4 , and R 5 are each hydrogen.
  • R 1 and R 3 are each independently halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 2 , R 4 , and R 5 are each hydrogen.
  • R 1 and R 4 are each independently halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 2 , R 3 , and R 5 are each hydrogen.
  • R 2 and R 3 are each independently hydrogen, halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 1 , R 4 , and R 5 are each hydrogen.
  • R 2 and R 3 are each independently halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 1 , R 4 , and R 5 are each hydrogen.
  • R 2 and R 3 are each independently benzyloxy, methoxy, fluoro, trifluoromethyl, or trifluoromethoxy.
  • R 2 and R 4 are each independently halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 1 , R 3 , and R 5 are each hydrogen.
  • R 3 and R 4 are each independently halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and R 1 , R 2 , and R 5 are each hydrogen.
  • R 5 is halogen, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl; and at least one of R 1 , R 2 , R 3 , and R 4 is not hydrogen.
  • representative compounds of Formula (I) include, but are not salts thereof, isotopically enriched variants thereof, and solvates thereof.
  • representative compounds of Formula (I) include, but are not isotopically enriched variants thereof, and solvates thereof.
  • a and B are each independently NR 7 or CHR 6a , wherein one of A and B is NR 7 and the other of A and B is CHR 6a ;
  • R 7 is Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted;
  • R 8 is hydrogen, Ci-ealkyl, Ci-eheteroalkyl, C i -ehaloalky 1, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted; each R 6a and each occurrence of R 6b is independently hydrogen, halogen, -OR a , -SR a , - NR b R c , -CN, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalky
  • R b and R c are each independently hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci- ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, arylalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or
  • R b and R c are taken together with the nitrogen to which they are attached to form an optionally substituted heterocycloalkyl ring.
  • each of R 1 , R 3 , and R 4 is hydrogen and the compound has the structure of Formula (IIA):
  • a and B are each independently NR 7 or CHR 6a , wherein one of A and B is NR 7 and the other of A and B is CHR 6a ;
  • - R 2 is hydrogen, -Br, -OR a , -SR a , -CN, C2-ealkyl, Ci-eheteroalkyl, C2-ehaloalkyl, Ci- ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted;
  • R 7 is Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted;
  • each R 6a and each occurrence of R 6b is independently hydrogen, halogen, -OR a , -SR a , - NR b R c , -CN, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted; each R 6a and each occurrence of R 6b is independently hydrogen, halogen, -OR a , -SR a , - NR b R c , -CN, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci
  • R b and R c are each independently hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci- ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, arylalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or
  • R b and R c are taken together with the nitrogen to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 7 and R 6a are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 7 and one occurrence of R 6b are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 6a and one occurrence of R 6b are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring or an optionally substituted cycloalkyl ring; or
  • - R 2 is hydrogen, -Br, -OR a , -SR a , -CN, C2-ealkyl, Ci-eheteroalkyl, C2-ehaloalkyl, Ci- ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R;
  • R 7 is Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R;
  • R 8 is hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R; each R 6a and each occurrence of R 6b is independently hydrogen, halogen, -OR a , -SR a , - NR b R c , -CN, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl
  • R -R b and R c are each independently hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci- ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, arylalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R; or
  • each of R 1 , R 2 , and R 4 is hydrogen and the compound has the structure of Formula (IIB):
  • a and B are each independently NR 7 or CHR 6a , wherein one of A and B is NR 7 and the remaining is CHR 6a ;
  • - R 3 is hydrogen, fluoro, chloro, -OR a , -SR a , -NR b R c , -CN, Ci-ealkyl, Ci-eheteroalkyl, Ci- ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, arylalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted;
  • - R 7 is Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted;
  • - R 8 is hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substitute
  • R b and R c are each independently hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci- ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, arylalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or
  • R b and R c are taken together with the nitrogen to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 7 and R 6a are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 7 and one occurrence of R 6b are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring;
  • R 6a and one occurrence of R 6b are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl ring or an optionally substituted cycloalkyl ring; or
  • R 3 is hydrogen, fluoro, chloro, -OR a , -SR a , -NR b R c , -CN, Ci-ealkyl, Ci-eheteroalkyl, Ci- ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, arylalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R;
  • R 7 is Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R;
  • R 8 is hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R; each R 6a and each occurrence of R 6b is independently hydrogen, halogen, -OR a , -SR a , - NR b R c , -CN, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci-ehydroxyalkyl, Ci-ealkoxy, Ci- eaminoalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl
  • R -R b and R c are each independently hydrogen, Ci-ealkyl, Ci-eheteroalkyl, Ci-ehaloalkyl, Ci- ehydroxyalkyl, Ci-ealkoxy, Ci-eaminoalkyl, aryl, arylalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, heteroalkyl, haloalkyl, hydroxyalkyl, alkoxy, aminoalkyl, aryl, arylalkyl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R; or
  • A is NR 7 and B is CHR 6a .
  • X is O, S, or NR 8 .
  • X is NR 8 .
  • R 8 is hydrogen or Ci-ealkyl optionally substituted with one or more R.
  • R 8 is hydrogen, methyl, ethyl, or isopropyl.
  • R 8 is hydrogen.
  • R 8 is methyl.
  • R 8 is ethyl.
  • R 8 is isopropyl.
  • R 7 is taken together with R 6a or one occurrence of R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R. In some embodiments, R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R.
  • R 7 is taken together with R 6a or one occurrence of R 6b and the intervening atoms to which they are attached to form an optionally substituted pyrrolidine, wherein the pyrrolidine is optionally substituted with one or more R.
  • R 7 is taken together with R 6a or one occurrence of R 6b and the intervening atoms to which they are attached to form a pyrrolidine.
  • each occurrence of R 6b is hydrogen or Ci-ealkyl optionally substituted with one or more R.
  • each occurrence of R 6b is hydrogen.
  • at least one occurrence of R 6b is methyl.
  • R 7 is taken together with one occurrence of R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R. In some embodiments, R 7 is taken together with one occurrence of R 6b and the intervening atoms to which they are attached to form an optionally substituted pyrrolidine, wherein the pyrrolidine is optionally substituted with one or more R. In some embodiments, R 7 is taken together with one occurrence of R 6b and the intervening atoms to which they are attached to form a pyrrolidine. In some embodiments, R 6a is hydrogen or Ci-ealkyl optionally substituted with one or more R. In some embodiments, R 6a is hydrogen. In some embodiments, R 6a is methyl.
  • R 7 is taken together with R 6a or one occurrence of R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R. In some embodiments, R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R.
  • R 7 is taken together with R 6a or one occurrence of R 6b and the intervening atoms to which they are attached to form an optionally substituted pyrrolidine, wherein the pyrrolidine is optionally substituted with one or more R.
  • R 7 is taken together with R 6a or one occurrence of R 6b and the intervening atoms to which they are attached to form a pyrrolidine.
  • each occurrence of R 6b is hydrogen or Ci-ealkyl optionally substituted with one or more R.
  • each occurrence of R 6b is hydrogen.
  • at least one occurrence of R 6b is methyl.
  • R 6a is hydrogen or Ci-ealkyl optionally substituted with one or more R. In some embodiments, R 6a is hydrogen. In some embodiments, R 6a is methyl. [00132] In some embodiments of Formula (IIA), A is NR 7 , B is CHR 6a , R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R, and wherein the compound of Formula (IIA) has the structure of Formula (IIA-1):
  • X is O, S, or NR 8 .
  • X is NR 8 .
  • R 8 is hydrogen or Ci-ealkyl optionally substituted with one or more R.
  • R 8 is hydrogen, methyl, ethyl, or isopropyl.
  • R 8 is hydrogen.
  • R 8 is methyl.
  • R 8 is ethyl.
  • R 8 is isopropyl.
  • m is 0, 1, or 2.
  • m is 1, 2 or 3.
  • m is 0 of 1.
  • m is 1 or 2.
  • m is 2 or 3.
  • m is 0.
  • m is 1.
  • m is 2.
  • m is 3.
  • n is 0-5. In some embodiments, n is 0-3. In some embodiments, n is 0-1.
  • n is 1-5. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. [00134] In some embodiments of Formula (IIA-1), X is NR 8 , n is 0, m is 1, and the compound has the structure of Formula (IIA-2):
  • R 8 is hydrogen or Ci-ealkyl optionally substituted with one or more R.
  • R 8 is hydrogen, methyl, ethyl, or isopropyl.
  • R 8 is hydrogen.
  • R 8 is methyl.
  • R 8 is ethyl.
  • R 8 is isopropyl.
  • A is NR 7
  • B is CH2
  • R 7 is taken together with one occurrence of R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R
  • the compound of Formula (IIA) has the structure of Formula (IIA-3):
  • m is 0, 1, or 2.
  • m is 1, 2 or 3.
  • m is 0 of 1.
  • m is 1 or 2.
  • m is 2 or 3.
  • m is 0.
  • m is 1.
  • m is 2.
  • m is 3.
  • n is 0-5.
  • n is 0-3.
  • n is 0-1. In some embodiments, n is 1-5.
  • X is NR 8 , n is 0, m is 1, and the compound has the structure of Formula (IIA-4):
  • R 8 is hydrogen or Ci-ealkyl optionally substituted with one or more R.
  • R 8 is hydrogen, methyl, ethyl, or isopropyl.
  • R 8 is hydrogen.
  • R 8 is methyl.
  • R 8 is ethyl.
  • R 8 is isopropyl.
  • R 2 is hydrogen, -Br, -OR a , -CN, C2-ealkyl, or C2-ehaloalkyl.
  • R a is Ci-ealkyl, Ci-ehaloalkyl, or arylalkyl.
  • R a is Ci- ealkyl, Ci-ehaloalkyl, or benzyl.
  • R a is methyl, ethyl, isopropyl, tert-butyl, - CF3, -CHF2,- CH2F, or benzyl.
  • R 2 is -OR a , and wherein R a is Ci-ehaloalkyl.
  • R 2 is -OR a , and wherein R a is arylalkyl.
  • R 2 is -OR a , and wherein R a is benzyl.
  • R 2 is -OR a , and wherein R a is Ci-ealkyl.
  • R 2 is hydrogen, benzyloxy, methoxy, or trifluoromethoxy. In some embodiments, R 2 is benzyloxy, methoxy, or trifluoromethoxy. In some embodiments, R 2 is hydrogen or methoxy. In some embodiments, R 2 is hydrogen. In some embodiments, R 2 is methoxy.
  • A is NR 7 ; B is CHR 6a ; R 7 is taken together with R 6a and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R, and wherein the compound of Formula (IIB) has the structure of Formula (IIB-1):
  • X is O, S, or NR 8 .
  • X is NR 8 .
  • R 8 is hydrogen or Ci-ealkyl optionally substituted with one or more R.
  • R 8 is hydrogen, methyl, ethyl, or isopropyl.
  • R 8 is hydrogen.
  • R 8 is methyl.
  • R 8 is ethyl.
  • R 8 is isopropyl.
  • m is 0, 1, or 2.
  • m is 1, 2 or 3.
  • m is 0 of 1.
  • m is 1 or 2.
  • m is 2 or 3.
  • m is 0.
  • m is 1.
  • m is 2.
  • m is 3.
  • n is 0-5. In some embodiments, n is 0-3. In some embodiments, n is 0-1.
  • n is 1-5. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7.
  • X is NR 8 , n is 0, m is 1, and the compound has the structure of Formula (IIB-2):
  • R 8 is hydrogen or Ci-ealkyl optionally substituted with one or more R.
  • R 8 is hydrogen, methyl, ethyl, or isopropyl.
  • R 8 is hydrogen.
  • R 8 is methyl.
  • R 8 is ethyl.
  • R 8 is isopropyl.
  • A is NR 7
  • B is CH2
  • R 7 is taken together with one occurrence of R 6b and the intervening atoms to which they are attached to form an optionally substituted heterocycloalkyl ring, wherein the heterocycloalkyl ring is optionally substituted with one or more R
  • the compound of Formula (IIB) has the structure of Formula (IIB-3):
  • X is O, S, or NR 8 .
  • X is NR 8 .
  • R 8 is hydrogen or Ci-ealkyl optionally substituted with one or more R.
  • R 8 is hydrogen, methyl, ethyl, or isopropyl.
  • R 8 is hydrogen.
  • R 8 is methyl.
  • R 8 is ethyl.
  • R 8 is isopropyl.
  • m is 0, 1, or 2.
  • m is 1, 2 or 3.
  • m is 0 of 1.
  • m is 1 or 2.
  • m is 2 or 3.
  • m is 0.
  • m is 1.
  • m is 2.
  • m is 3.
  • n is 0-5.
  • n is 0-3.
  • n is 0-1. In some embodiments, n is 1-5.
  • n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7.
  • X is NR 8 , n is 0, m is 1, and the compound has the structure of Formula (IIB-4):
  • R 8 is hydrogen or Ci-ealkyl optionally substituted with one or more R.
  • R 8 is hydrogen, methyl, ethyl, or isopropyl.
  • R 8 is hydrogen.
  • R 8 is methyl.
  • R 8 is ethyl.
  • R 8 is isopropyl.
  • R 3 is hydrogen, fluoro, chloro, -OR a , -CN, Ci-ealkyl, or Ci- ehaloalkyl.
  • R a is Ci-ealkyl, Ci-ehaloalkyl, or arylalkyl.
  • R a is Ci-ealkyl, Ci-ehaloalkyl, or benzyl.
  • R a is methyl, ethyl, isopropyl, tert-butyl, -CF3, -CHF2,- CH2F, or benzyl.
  • R 3 is hydrogen, fluoro, chloro, -OR a , -CN, Ci-ealkyl, or Ci-ehaloalkyl.
  • R a is Ci-ealkyl, Ci-ehaloalkyl, or arylalkyl.
  • R 3 is -OR a , and wherein R a is Ci-ehaloalkyl.
  • R 3 is -OR a , and wherein R a is arylalkyl.
  • R 3 is -OR a , and wherein R a is benzyl. In some embodiments, R 3 is -OR a , and wherein R a is Ci-ealkyl. In some embodiments, R 3 is hydrogen, benzyloxy, methoxy, fluoro, trifluoromethyl, or trifluoromethoxy. In some embodiments, R 3 is benzyloxy, methoxy, fluoro, trifluoromethyl, or trifluoromethoxy. In some embodiments, R 3 is Ci-ehaloalkyl. In some embodiments, R 3 is hydrogen, fluoro, chloro, or methoxy. In some embodiments, R 3 is hydrogen. In some embodiments, R 3 is fluoro, chloro, or methoxy.
  • representative compounds of Formula (II) include, but are not pharmaceutically acceptable salts thereof, isotopically enriched variants thereof, and solvates thereof.
  • a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or the stereoisomer having a structure provided in Table 1.
  • compounds described herein are in the form of pharmaceutically acceptable salts.
  • any compound provided herein is a pharmaceutically acceptable salt, such as, for example, any salt described herein (such as, e.g., a fumarate salt of the compound provided herein or maleate salt of the compound provided herein).
  • any compound provided herein is a fumarate salt of the compound provided herein.
  • any compound provided herein is a maleate salt of the compound provided herein.
  • pharmaceutically acceptable salts are obtained by reacting a compound Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), for example any compound described in Table 1, with an acid.
  • Inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and metaphosphoric acid.
  • Organic acids include, but are not limited to, 1 -hydroxy -2-naphthoic acid; 2, 2-di chloroacetic acid; 2- hydroxyethanesulfonic acid; 2-oxoglutaric acid; 4-acetamidobenzoic acid; 4-aminosalicylic acid; acetic acid; adipic acid; ascorbic acid (L); aspartic acid (L); benzenesulfonic acid; benzoic acid; camphoric acid (+); camphor- 10-sulfonic acid (+); capric acid (decanoic acid); caproic acid (hexanoic acid); caprylic acid (octanoic acid); carbonic acid; cinnamic acid; citric acid; cyclamic acid; dodecylsulfuric acid; ethane- 1,2-disulfonic acid; ethanesulfonic acid; formic acid; fumaric acid; galactaric acid; gentisic acid; glucoheptonic acid (
  • Table 1 i.e. free base form
  • Table 1 i.e. free base form
  • pharmaceutically acceptable salts are obtained by reacting a compound represented by the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), for example any compound described in Table l,with a base.
  • a metal ion e.g., lithium, sodium, potassium, magnesium, calcium, or an aluminum ion.
  • compounds described herein coordinate with an organic base, such as, but not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, meglumine, N- methylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine.
  • compounds described herein form salts with amino acids such as, but not limited to, arginine, lysine, and the like.
  • Acceptable inorganic bases used to form salts with compounds that include an acidic proton include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydroxide, lithium hydroxide, and the like.
  • the compounds provided herein are prepared as a sodium salt, calcium salt, potassium salt, magnesium salt, meglumine salt, N-methylglucamine salt or ammonium salt.
  • solvates contain either stoichiometric or non- stoichiometric amounts of a solvent, and are formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds described herein are conveniently prepared or formed during the processes described herein. In addition, the compounds provided herein optionally exist in unsolvated as well as solvated forms.
  • the methods and formulations described herein include the use of A-oxides (if appropriate), or pharmaceutically acceptable salts of compounds having the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), as well as active metabolites of these compounds having the same type of activity.
  • sites on the organic radicals (e.g. alkyl groups, aromatic rings) of compounds of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), are susceptible to various metabolic reactions.
  • the appropriate substituent to decrease or eliminate the susceptibility of the aromatic ring to metabolic reactions is, by way of example only, a halogen, deuterium, an alkyl group, a haloalkyl group, or a deuteroalkyl group.
  • the compounds described herein are labeled isotopically (e.g. with a radioisotope) or by another other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
  • Compounds described herein include isotopically-labeled compounds, which are identical to those recited in the various formulae and structures presented herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into the present compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine chlorine, iodine, phosphorus, such as, for example, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 35 S, 18 F, 125 1, 131 1, 32 P and 33 P.
  • isotopically-labeled compounds described herein for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays.
  • substitution with isotopes such as deuterium affords certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements.
  • the compounds presented herein include all diastereomeric, individual enantiomers, atropisomers, and epimeric forms as well as the appropriate mixtures thereof.
  • the compounds and methods provided herein include all cis, trans, syn, anti,
  • a composition provided herein comprises a racemic mixture of a compound represented by a structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), for example any compound described in Table 1.
  • a compound provided herein is a racemate of a compound represented by a structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), for example any compound described in Table 1.
  • stereoisomers are obtained, if desired, by methods such as, stereoselective synthesis and/or the separation of stereoisomers by chiral chromatographic columns or the separation of diastereomers by either non-chiral or chiral chromatographic columns or crystallization and recrystallization in a proper solvent or a mixture of solvents.
  • a compound represented by the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), for example any compound described in Table 1, is prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds/salts, separating the diastereomers and recovering the optically pure individual enantiomers.
  • resolution of individual enantiomers is carried out using covalent diastereomeric derivatives of the compounds described herein.
  • diastereomers are separated by separation/resolution techniques based upon differences in solubility.
  • separation of stereoisomers is performed by chromatography or by the forming diastereomeric salts and separation by recrystallization, or chromatography, or any combination thereof. Jean Jacques, Andre Collet, Samuel H. Wilen, “Enantiomers, Racemates and Resolutions”, John Wiley And Sons, Inc., 1981.
  • stereoisomers are obtained by stereoselective synthesis.
  • a prodrug is an agent that is converted into the parent drug in vivo.
  • Prodrugs are often useful because, in some situations, they are easier to administer than the parent drug. They are, for embodiment, bioavailable by oral administration whereas the parent is not. Further or alternatively, the prodrug also has improved solubility in pharmaceutical compositions over the parent drug.
  • the design of a prodrug increases the effective water solubility.
  • An example, without limitation, of a prodrug is a compound described herein, which is administered as an ester (the “prodrug”) but then is metabolically hydrolyzed to provide the active entity.
  • a further example of a prodrug is a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety.
  • a prodrug upon in vivo administration, is chemically converted to the biologically, pharmaceutically or therapeutically active form of the compound.
  • a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound.
  • Prodrugs of the compounds described herein include, but are not limited to, esters, ethers, carbonates, thiocarbonates, N-acyl derivatives, N-acyloxyalkyl derivatives, N-alkyloxyacyl derivatives, quaternary derivatives of tertiary amines, N-Mannich bases, Schiff bases, amino acid conjugates, phosphate esters, and sulfonate esters. See for example Design of Prodrugs, Bundgaard, A. Ed., Elseview, 1985 and Method in Enzymology, Widder, K. et al., Ed.; Academic, 1985, vol. 42, p. 309-396; Bundgaard, H.
  • a hydroxyl group in the compounds disclosed herein is used to form a prodrug, wherein the hydroxyl group is incorporated into an acyloxyalkyl ester, alkoxycarbonyloxyalkyl ester, alkyl ester, aryl ester, phosphate ester, sugar ester, ether, and the like.
  • a hydroxyl group in the compounds disclosed herein is a prodrug wherein the hydroxyl is then metabolized in vivo to provide a carboxylic acid group.
  • a carboxyl group is used to provide an ester or amide (i.e. the prodrug), which is then metabolized in vivo to provide a carboxylic acid group.
  • compounds described herein are prepared as alkyl ester prodrugs.
  • Prodrug forms of the herein described compounds wherein the prodrug is metabolized in vivo to produce a compound of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IEB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), as set forth herein are included within the scope of the claims.
  • any one of the hydroxyl group(s), amino group(s) and/or carboxylic acid group(s) are functionalized in a suitable manner to provide a prodrug moiety.
  • the prodrug moiety is as described above.
  • the compounds described herein are metabolized upon administration to an organism in need to produce a metabolite that is then used to produce a desired effect, including a desired therapeutic effect.
  • a metabolite of a compound disclosed herein is a derivative of that compound that is formed when the compound is metabolized.
  • an “active metabolite” of a compound provided herein is a biologically active derivative of the compound provided herein that is formed when the compound is metabolized.
  • metabolism is the sum of the processes (including, but not limited to, hydrolysis reactions and reactions catalyzed by enzymes) by which a particular substance is changed by an organism.
  • enzymes may produce specific structural alterations to a compound.
  • cytochrome P450 catalyzes a variety of oxidative and reductive reactions while uridine diphosphate glucuronyltransferases catalyze the transfer of an activated glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines and free sulfhydryl groups.
  • a metabolite of a compound disclosed herein is optionally identified either by administration of compounds to a host and analysis of tissue samples from the host, or by incubation of compounds with hepatic cells in vitro and analysis of the resulting compounds.
  • a pharmaceutical composition comprising a compound provided herein (e.g., a compound having a structure represented by Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (HB-3), or (IIB-4), for example any compound described in Table 1, and a pharmaceutically acceptable salt or solvate thereof.
  • the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.
  • the compounds described herein are formulated into pharmaceutical compositions.
  • Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that are used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • a summary of pharmaceutical compositions described herein is found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A.
  • the compounds described herein are administered either alone or in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition.
  • Administration of the compounds and compositions described herein can be affected by any method that enables delivery of the compounds to the site of action.
  • enteral routes including oral, gastric or duodenal feeding tube, rectal suppository and rectal enema
  • parenteral routes injection or infusion, including intraarterial, intracardiac, intradermal, intraduodenal, intramedullary, intramuscular, intraosseous, intraperitoneal, intrathecal, intravascular, intravenous, intravitreal, epidural and subcutaneous), inhalational, transdermal, transmucosal, sublingual, buccal and topical (including epicutaneous, dermal, enema, eye drops, ear drops, intranasal, vaginal) administration, although the most suitable route may depend upon for example the condition and disorder of the recipient.
  • compounds described herein can be administered locally to the area in need of treatment, by for example, local infusion during surgery, topical application such as creams or ointments, injection, catheter, or implant.
  • topical application such as creams or ointments, injection, catheter, or implant.
  • the administration can also be by direct injection at the site of a diseased tissue or organ.
  • compositions suitable for oral administration are presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient is presented as a bolus, electuary or paste.
  • compositions which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets are coated or scored and are formulated so as to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In some embodiments, stabilizers are added. Dragee cores are provided with suitable coatings.
  • concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or Dragee coatings for identification or to characterize different combinations of active compound doses.
  • compositions are formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use.
  • sterile liquid carrier for example, saline or sterile pyrogen-free water
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • compositions for parenteral administration include aqueous and nonaqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • compositions described herein may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • the compounds disclosed herein, or pharmaceutically acceptable salts, solvates, or stereoisomers thereof, are useful for promoting neuronal growth and/or improving neuronal structure.
  • non-hallucinogenic psychoplastogens that useful for treating one or more diseases or disorders associated with loss of synaptic connectivity and/or plasticity.
  • a method of promoting neural plasticity in an individual by administering a compound described herein (e.g., a compound represented by the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), for example any compound described in Table 1, to the individual.
  • a compound described herein e.g., a compound represented by the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), for example any compound described in Table 1, to the individual.
  • a compound described herein e.g., a compound represented by the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), for example any compound described in Table 1, to the individual.
  • a compound described herein e.g., a compound represented by the structure of Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), for example any compound described in Table 1, to the individual.
  • the individual has or is diagnosed with a brain disorder or other conditions described herein.
  • a method of promoting neuronal growth in an individual in need thereof comprising administering to the individual in need thereof a therapeutically effective amount of a compound or pharmaceutical composition provided herein (e.g., a compound having a structure represented by Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), for example any compound described in Table 1).
  • a compound or pharmaceutical composition provided herein (e.g., a compound having a structure represented by Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (II
  • a method of improving neuronal structure in an individual in need thereof comprising administering to the individual in need thereof a therapeutically effective amount of a compound or pharmaceutical composition provided herein (e.g., a compound having a structure represented by Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), for example any compound described in Table 1).
  • a compound or pharmaceutical composition provided herein (e.g., a compound having a structure represented by Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB
  • a method of modulating the activity of 5- hydroxytryptamine receptor 2A (5-HT2A) receptor in an individual in need thereof comprising administering to the individual in need thereof a therapeutically effective amount of a compound or pharmaceutical composition provided herein (e.g., a compound having a structure represented by Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), or for example any compound described in Table 1).
  • a compound or pharmaceutical composition provided herein (e.g., a compound having a structure represented by Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1
  • a method of treating a disease or disorder in an individual in need thereof that is mediated by the action of 5-hydroxytryptamine (5-HT) at 5- hydroxytryptamine receptor 2A (5-HT2A), comprising administering to the individual in need thereof a therapeutically effective amount of a compound or pharmaceutical composition provided herein (e.g., a compound having a structure represented by Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), or for example any compound described in Table 1).
  • a compound or pharmaceutical composition provided herein (e.g., a compound having a structure represented by Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-2), (IIA
  • a method of treating a disease or disorder in an individual in need thereof that is mediated by the loss of synaptic connectivity, plasticity, or a combination thereof comprising administering to the individual in need thereof a therapeutically effective amount of a compound or pharmaceutical composition provided herein (e.g., a compound having a structure represented by Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB), (IIB-1), (IIB-2), (IIB-3), or (IIB-4), or for example any compound described in Table 1).
  • a compound or pharmaceutical composition provided herein (e.g., a compound having a structure represented by Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (IIB),
  • a method of treating a neurological disease or disorder in an individual in need thereof comprising administering to the individual in need thereof a therapeutically effective amount of a compound or pharmaceutical composition provided herein (e.g., a compound having a structure represented Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (HB), (HB-1), (IIB-2), (IIB-3), or (IIB-4), or for example any compound described in Table 1).
  • a compound or pharmaceutical composition provided herein (e.g., a compound having a structure represented Formula (I), (IA), (IA-1), (IB), (IB-1), (II), (IIA), (IIA-1), (IIA-2), (IIA-3), (IIA-4), (HB), (HB-1), (IIB-2), (IIB-3), or (IIB-4),
  • an individual administered a compound provided herein has a hallucinogenic event. In some embodiments, an individual administered a compound provided herein does not have a hallucinogenic event. In some embodiments, an individual administered a compound provided herein has a hallucinogenic event after the compound provided herein reaches a particular maximum concentration (Cmax) in the individual. In some embodiments, the particular maximum concentration (Cmax) in the individual is the hallucinogenic threshold of the compound provided herein. In some embodiments, a compound provided herein is administered to an individual in need thereof below the hallucinogenic threshold of the compound provided herein. [00195] In some embodiments, described herein are methods for treating a disease or disorder, wherein the disease or disorder is a neurological diseases and disorder.
  • a compound of the present disclosure is used to treat neurological diseases.
  • a compound provided herein has, for example, anti -addictive properties, antidepressant properties, anxiolytic properties, or a combination thereof.
  • the neurological disease is a neuropsychiatric disease.
  • the neuropsychiatric disease is a mood or anxiety disorder.
  • the neurological disease is a migraine, headaches (e.g., cluster headache), post-traumatic stress disorder (PTSD), anxiety, depression, neurodegenerative disorder, Alzheimer’s disease, Parkinson’s disease, psychological disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and addiction (e.g., substance use disorder).
  • the neurological disease is a migraine or cluster headache.
  • the neurological disease is a neurodegenerative disorder, Alzheimer’s disease, or Parkinson’s disease.
  • the neurological disease is a psychological disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), depression, or anxiety.
  • the neuropsychiatric disease is a psychological disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), depression, or anxiety.
  • the neuropsychiatric disease or neurological disease is post-traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), schizophrenia, depression, or anxiety.
  • the neuropsychiatric disease or neurological disease is addiction (e.g., substance use disorder). In some embodiments, the neuropsychiatric disease or neurological disease is depression. In some embodiments, the neuropsychiatric disease or neurological disease is anxiety. In some embodiments, the neuropsychiatric disease or neurological disease is post-traumatic stress disorder (PTSD). In some embodiments, the neurological disease is stroke or traumatic brain injury. In some embodiments, the neuropsychiatric disease or neurological disease is schizophrenia.
  • addiction e.g., substance use disorder
  • the neuropsychiatric disease or neurological disease is depression. In some embodiments, the neuropsychiatric disease or neurological disease is anxiety. In some embodiments, the neuropsychiatric disease or neurological disease is post-traumatic stress disorder (PTSD). In some embodiments, the neurological disease is stroke or traumatic brain injury. In some embodiments, the neuropsychiatric disease or neurological disease is schizophrenia.
  • a compound disclosed herein, or pharmaceutically acceptable salts, solvates, or stereoisomers thereof is useful for the modulation of a 5-hydroxytryptamine (5-HT) receptor.
  • the 5-HT receptor modulated by the compounds and methods is 5- hydroxytryptamine receptor 2A (5-HT2A).
  • modulators of 5-hydroxytryptamine receptor 2A that are useful for treating one or more diseases or disorders associated with 5-HT2A activity.
  • a compound described herein, or a pharmaceutically acceptable salt thereof are used in the preparation of medicaments for the treatment of diseases or conditions in a mammal that would benefit from inhibition or reduction of 5-HT2A activity.
  • a compound described herein, or a pharmaceutically acceptable salt thereof are used in the preparation of medicaments for the treatment of diseases or conditions in a mammal that would benefit from promoting neuronal growth and/or improving neuronal structure.
  • Methods for treating any of the diseases or conditions described herein in a mammal in need of such treatment involves administration of pharmaceutical compositions that include at least one compound described herein or a pharmaceutically acceptable salt, active metabolite, prodrug, or pharmaceutically acceptable solvate thereof, in therapeutically effective amounts to said mammal.
  • compositions containing the compound(s) described herein are administered for prophylactic and/or therapeutic treatments.
  • the compositions are administered to a mammal already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest at least one of the symptoms of the disease or condition. Amounts effective for this use depend on the severity and course of the disease or condition, previous therapy, the mammal’s health status, weight, and response to the drugs, and the judgment of a healthcare practitioner.
  • Therapeutically effective amounts are optionally determined by methods including, but not limited to, a dose escalation and/or dose ranging clinical trial.
  • compositions containing the compounds described herein are administered to a mammal susceptible to or otherwise at risk of a particular disease, disorder or condition.
  • a mammal susceptible to or otherwise at risk of a particular disease, disorder or condition is defined to be a “prophylactically effective amount or dose.”
  • the precise amounts also depend on the mammal’s state of health, weight, and the like.
  • effective amounts for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the mammal’s health status and response to the drugs, and the judgment of a healthcare professional.
  • prophylactic treatments include administering to a mammal, who previously experienced at least one symptom of the disease being treated and is currently in remission, a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt thereof, in order to prevent a return of the symptoms of the disease or condition.
  • the administration of the compounds are administered chronically, that is, for an extended period of time, including throughout the duration of the mammal’s life in order to ameliorate or otherwise control or limit the symptoms of the mammal’s disease or condition.
  • the dose of drug being administered is temporarily reduced or temporarily suspended for a certain length of time (z.e., a “drug holiday”).
  • the length of the drug holiday is between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, or more than 28 days.
  • the dose reduction during a drug holiday is, by way of example only, by 10%-100%, including by way of example only 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%.
  • a maintenance dose is administered if necessary. Subsequently, in specific embodiments, the dosage or the frequency of administration, or both, is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. In certain embodiments, however, the mammal requires intermittent treatment on a long-term basis upon any recurrence of symptoms.
  • the amount of a given agent that corresponds to such an amount varies depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight, sex) of the subject or host in need of treatment, but nevertheless is determined according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated.
  • doses employed for adult human treatment are typically in the range of 0.01 mg-5000 mg per day. In one embodiment, doses employed for adult human treatment are from about 1 mg to about 1000 mg per day. In one embodiment, the desired dose is conveniently presented in a single dose or in divided doses administered simultaneously or at appropriate intervals, for example as two, three, four or more sub-doses per day.
  • the daily dosages appropriate for the compound described herein, or a pharmaceutically acceptable salt thereof are from about 0.01 to about 50 mg/kg per body weight. In some embodiments, the daily dosage or the amount of active in the dosage form are lower or higher than the ranges indicated herein, based on a number of variables in regard to an individual treatment regime. In various embodiments, the daily and unit dosages are altered depending on a number of variables including, but not limited to, the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.
  • Toxicity and therapeutic efficacy of such therapeutic regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LD50 and the ED50.
  • the dose ratio between the toxic and therapeutic effects is the therapeutic index and it is expressed as the ratio between LD50 and ED50.
  • the data obtained from cell culture assays and animal studies are used in formulating the therapeutically effective daily dosage range and/or the therapeutically effective unit dosage amount for use in mammals, including humans.
  • the daily dosage amount of the compounds described herein lies within a range of circulating concentrations that include the ED50 with minimal toxicity.
  • the daily dosage range and/or the unit dosage amount varies within this range depending upon the dosage form employed and the route of administration utilized.
  • any of the aforementioned aspects are further embodiments in which the effective amount of the compound described herein, or a pharmaceutically acceptable salt thereof, is: (a) systemically administered to the mammal; and/or (b) administered orally to the mammal; and/or (c) intravenously administered to the mammal; and/or (d) administered by injection to the mammal; and/or (e) administered topically to the mammal; and/or (f) administered non-systemically or locally to the mammal.
  • any of the aforementioned aspects are further embodiments comprising single administrations of the effective amount of the compound, including further embodiments in which (i) the compound is administered once a day; or (ii) the compound is administered to the mammal multiple times over the span of one day.
  • any of the aforementioned aspects are further embodiments comprising multiple administrations of the effective amount of the compound, including further embodiments in which (i) the compound is administered continuously or intermittently: as in a single dose; (ii) the time between multiple administrations is every 6 hours; (iii) the compound is administered to the mammal every 8 hours; (iv) the compound is administered to the mammal every 12 hours; (v) the compound is administered to the mammal every 24 hours.
  • the method comprises a drug holiday, wherein the administration of the compound is temporarily suspended or the dose of the compound being administered is temporarily reduced; at the end of the drug holiday, dosing of the compound is resumed.
  • the length of the drug holiday varies from 2 days to 1 year.
  • the therapeutic effectiveness of one of the compounds described herein is enhanced by administration of an adjuvant (z.e., by itself the adjuvant has minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced).
  • an adjuvant z.e., by itself the adjuvant has minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced.
  • the benefit experienced by a patient is increased by administering one of the compounds described herein with another agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
  • different therapeutically-effective dosages of the compounds disclosed herein will be utilized in formulating pharmaceutical composition and/or in treatment regimens when the compounds disclosed herein are administered in combination with one or more additional agent, such as an additional therapeutically effective drug, an adjuvant or the like.
  • additional agent such as an additional therapeutically effective drug, an adjuvant or the like.
  • Therapeutically-effective dosages of drugs and other agents for use in combination treatment regimens is optionally determined by means similar to those set forth hereinabove for the actives themselves.
  • the methods of prevention/treatment described herein encompasses the use of metronomic dosing, i.e., providing more frequent, lower doses in order to minimize toxic side effects.
  • a combination treatment regimen encompasses treatment regimens in which administration of a compound described herein, or a pharmaceutically acceptable salt thereof, is initiated prior to, during, or after treatment with a second agent described herein, and continues until any time during treatment with the second agent or after termination of treatment with the second agent. It also includes treatments in which a compound described herein, or a pharmaceutically acceptable salt thereof, and the second agent being used in combination are administered simultaneously or at different times and/or at decreasing or increasing intervals during the treatment period. Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient.
  • the dosage regimen to treat, prevent, or ameliorate the disease(s) for which relief is sought is modified in accordance with a variety of factors (e.g. the disease or disorder from which the subject suffers; the age, weight, sex, diet, and medical condition of the subject).
  • the dosage regimen actually employed varies and, in some embodiments, deviates from the dosage regimens set forth herein.
  • Nuclear magnetic resonance (NMR) spectra are acquired on either a Bruker 400 operating at 400 and 100 MHz, a Varian 400 operating at 400 and 100 MHz, or a Varian 500 operating at 500 and 125 MHz for 'H and 13 C, respectively, and are referenced internally according to residual solvent signals.
  • Data for 'H NMR are recorded as follows: chemical shift (5, ppm), multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet), coupling constant (Hz), and integration.
  • Data for 13 C NMR are reported in terms of chemical shift (5, ppm).
  • Liquid chromatography-mass spectrometry (LC-MS) is performed using an Agilent LC-MS with Ion Trap or ELSD detector, or a Waters LC-MS with an UPLC detector.
  • Example 1 General synthetic scheme for azepine-indoles:
  • Int-14 was prepared as described for Int-14 but using Int-12 as the starting material.
  • Int-16 was prepared as described for Int-15 but using Int-14 as the starting material.
  • Example 21 Preparation of Int-18 (tert-butyl 2-((5-methoxy-l-(2-(tosyloxy)ethyl)-lH-indol-2- yl)methyl)pyrrolidine-l-carboxylate): lnt-18
  • Racemic Compound 2(90 mg) was separated into its enantiomers by using chiral HPLC (Chiralpak IG 250 x 4.6mm 5pm, 95% 0.1% DEA in n-Hexane gradient of 5% IPA, 35.0 mL/min). The faster eluting peak was assigned as Compound 7 and the more slowly eluting peak was assigned as Compound 8.
  • Compound 3 was prepared as described for Compound 2 but using Int-18 as the starting material.
  • 12 mg of Compound 3 free base was treated with an excess of HC1 solution in MeOH to afford 3 mg of Compound 3 HC1 salt.
  • Example 26 Preparation of Compound 15 ((S)-2,3,5,10,ll,lla-hexahydro-lH-indolizino[7,6- bjindole) & Compound 16 ((R)-2,3,5,10,ll,lla-hexahydro-lH-indolizino[7,6-b]indole): Compound 15 Compound 16
  • Racemic Compound 12 (50 mg) was separated into its enantiomers by using chiral HPLC (Chiralpak IG 250 x 4.6mm 5pm, 75% 0.1% DEA in n-Hexane gradient of 25% MeOH:CH2C12 (50:50), 35.0 mL/min).
  • the faster eluting peak was assigned as Compound 15 (15 mg) and the more slowly eluting peak was assigned as Compound 16 (20 mg).
  • Example 28 Preparation Compound 10 ((S)-8-methoxy-2,3,5,10,ll,lla-hexahydro-lH- indolizino [7, 6-b] indole) & Compound 11 ((R)-8-methoxy-2,3,5,10,ll,Ha-hexahydro-lH- indolizino[7,6-b]indole):
  • Racemic Compound 9 (20 mg) was separated into its enantiomers by using chiral HPLC (Chiralpak IG 250 x 4.6mm 5pm, 75% 0.1% DEA in n-Hexane gradient of 25% MeOH:CH2C12 (50:50), 35.0 mL/min). The faster eluting peak was assigned as Compound 10 and the more slowly eluting peak was assigned as Compound 11.
  • Example 29 Preparation of Compound 13 (7-methoxy-2,3,5,10,ll,Ha-hexahydro-lH- indolizino [7, 6-b] indole) & Compound 17 (10-methoxy-2,3,5,6,7,llc-hexahydro-lH- indolizino[7,8-b]indole):
  • Compound 18 was prepared as described for Compound 12 but using 3 -fluorophenyl hydrazine hydrochloride as the starting material.
  • Compound 14 was prepared as described for Compound 12 but using 4-fluorophenyl hydrazine hydrochloride as the starting material.
  • Example A-l Parenteral Pharmaceutical Composition
  • a parenteral pharmaceutical composition suitable for administration by injection (subcutaneous, intravenous)
  • 1-1000 mg of a water-soluble salt of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, is dissolved in sterile water and then mixed with 10 mL of 0.9% sterile saline.
  • a suitable buffer is optionally added as well as optional acid or base to adjust the pH.
  • the mixture is incorporated into a dosage unit form suitable for administration by injection.
  • a sufficient amount of a compound described herein, or a pharmaceutically acceptable salt thereof is added to water (with optional solubilizer(s), optional buffer(s) and taste masking excipients) to provide a 20 mg/mL solution.
  • a tablet is prepared by mixing 20-50% by weight of a compound described herein, or a pharmaceutically acceptable salt thereof, 20-50% by weight of microcrystalline cellulose, and 1- 10% by weight of magnesium stearate or other appropriate excipients. Tablets are prepared by direct compression. The total weight of the compressed tablets is maintained at 100 -500 mg.
  • a pharmaceutical composition for oral delivery 1-1000 mg of a compound described herein, or a pharmaceutically acceptable salt thereof, is mixed with starch or other suitable powder blend. The mixture is incorporated into an oral dosage unit such as a hard gelatin capsule, which is suitable for oral administration.
  • 1-1000 mg of a compound described herein, or a pharmaceutically acceptable salt thereof is placed into Size 4 capsule, or size 1 capsule (hypromellose or hard gelatin) and the capsule is closed.
  • Hallucinogenic compound 5-MeO-DMT produces a robust, dose-dependent head-twitch response (HTR) in mice.
  • HTR head-twitch response
  • 6-MeO-DMT is significantly less potent.
  • 6-MeO-DMT does not produce a HTR.
  • potent plasticity -promoting compounds do not produce a HTR, demonstrating that hallucinogenic potential and psychoplastogenicity can be decoupled.
  • Hallucinogens e.g., LSD and 5-MeO-DMT
  • LSD and 5-MeO-DMT can activate a 5HT2A sensor assay in agonist mode, but their non-hallucinogenic congeners (lisuride (LIS) and 6-MeO-DMT) may not.
  • compounds such as, for example, 5-MeO-DMT, LSD, DMT, DOI, which are hallucinogenic in animals (e.g., humans), activate the 5HT2A sensor assay in agonist mode
  • compounds such as, for example, 6-MeO-DMT, LIS, 6-F-DET, L-MDMA, R-MDMA, Ketanserin, BOL148, which are non-hallucinogenic in animals (e.g., humans), do not activate the 5HT2A sensor assay in agonist mode.
  • hallucinogenic potential of a compound provided herein is determined in vitro.
  • hallucinogenic potential of a compound provided herein is determined using a 5HT2A sensor assay.
  • the 5HT2A sensor assay is in an agonist mode or an antagonist mode. In some embodiments, the 5HT2A sensor assay is in an agonist mode. In some embodiments, a compound provided herein does not activate the sensor in agonist mode and has non-hallucinogenic potential. In some embodiments, a compound of provided herein does not activate the sensor in agonist mode and is a non-hallucinogenic compound.
  • the hallucinogenic potential of the compound provided herein are assessed in a 5HT2A sensor assay in an agonist mode.
  • non-hallucinogenic compounds e.g., lisuride and 6- MeO-DMT
  • compounds such as, for example, 6-F-DET, Ketanserin, BOL148, which are non- hallucinogenic in animals (e.g., humans)
  • a compound provided herein prevents binding of 5-HT to 5HT2A.
  • the 5HT2A sensor assay is in an antagonist mode.
  • a compound provided herein prevents binding of 5-HT to 5HT2A and has non- hallucinogenic potential.
  • a compound provided herein prevents binding of 5-HT to 5HT2A and is non-hallucinogenic. In some embodiments, a compound provided herein prevents binding of 5-HT to 5HT2A in antagonist mode has non-hallucinogenic potential. In some embodiments, a compound provided herein that prevents binding of 5-HT in antagonist mode is a non-hallucinogenic compound. In some embodiments, a compound provided herein that inhibits the response of the sensor assay in antagonist mode has non-hallucinogenic potential. In some embodiments, a compound provided herein that inhibits the response of the sensor assay in antagonist mode is a non-hallucinogenic compound.
  • the results for the agonist mode sensor assay suggests a compound provided herein is a non-hallucinogenic ligand of the 5-HT2A receptor.
  • the results for the antagonist mode sensor assay suggests a compound provided herein is a non- hallucinogenic ligand of the 5-HT2A receptor.
  • the results for the agonist mode and antagonist mode sensor assay together suggest a compound provided herein is a non- hallucinogenic ligand of the 5-HT2A receptor.
  • the hallucinogenic potential of the compounds are assessed in a 5HT2A sensor assay in an antagonist mode.
  • Example B-2 Forced Swim Test (FST).
  • mice undergo a 15 min swim session (pre-swim), lasting for 15 minutes, dried with paper towels, and returned to the home cage. Rats are injected with either saline, ketamine (positive control), or test compound after the habituation session, returned to home cage, and then tested in a second FST lasting 5 minutes ⁇ 24 hours (second swim test) later.
  • the second swim test is video recorded for scoring. Body weights are measured on both days. Scoring of the second swim test is performed by trained technicians using a time sampling technique in which the animal in the video recorded test is viewed every 5 seconds and the behavior seen is noted. The measures noted are immobility, climbing, and swimming behaviors.
  • Example B-3 Neurite outgrowth assay.
  • Changes in the pattern of neurite outgrowth have been implicated in neurodegenerative disorders as well as traumatic injuries. The discovery of compounds that can positively affect neuritogenesis are important for developing new therapeutics for neurological diseases.
  • measurement of neurite outgrowth of rat cortical neurons using an automated imagebased assay is used to determine the neuroplastic effects of the compounds provided herein.
  • a compound provided herein increases the pattern of neurite outgrowth.
  • a compound provided herein increases neurite average length compared to a control.
  • a compound provided herein increases neurite branch points compared to a control.
  • a compound provided herein increases neurite average length and neurite branch points compared to a control.
  • the plastogenic potential of compounds provided herein is assessed by measuring the changes in neurite development.
  • Example B-4 Dendritogenesis Assays.
  • Phenotypic screening has historically proven more successful than target-based approaches for identifying drugs with novel mechanisms of action.
  • the compounds provided herein are tested for their ability to increase dendritic arbor complexity in cultures of cortical neurons. Following treatment, neurons are fixed and visualized using an antibody against MAP2 — a cytoskeletal protein localized to the somatodendritic compartment of neurons. Sholl analysis is then performed, and the maximum number of crossings (Nmax) is used as a quantitative metric of dendritic arbor complexity. For statistical comparisons between specific compounds, the raw Nmax values are compared. Percent efficacies are determined by setting the Nmax values for the vehicle (DMSO) and positive (ketamine) controls equal to 0% and 100%, respectively.
  • DMSO vehicle
  • ketamine ketamine
  • mice Animals. For the dendritogenesis experiments, timed pregnant Sprague Dawley rats are obtained from Charles River Laboratories (Wilmington, MA). In some instances, male and female C57BL/6J mice are obtained from Jackson Laboratory (Sacramento, C. A.). In some instances, mice are housed in a temperature and humidity-controlled room maintained on a 12-h light/dark cycle in groups of 4-5 (same sex).
  • Example B-5 Dendritogenesis - Sholl Analysis.
  • Neurons are plated in 96-well format (200 pL of media per well) at a density of approximately 15,000 cells/well in Neurobasal (Life Technologies) containing 1% penicillinstreptomycin, 10% heat-inactivated fetal bovine serum, and 0.5 mM glutamine. After 24 h, the medium is replaced with Neurobasal containing lx B27 supplement (Life Technologies), 1% penicillin-streptomycin, 0.5 mM glutamine, and 12.5 pM glutamate. After 3 days in vitro (DIV3), the cells are treated with compounds. Compounds tested in the dendritogenesis assays are treated at 10 pM unless noted otherwise.
  • the cells are incubated at room temperature for 20 min before the fixative is aspirated and each well washed twice with DPBS.
  • Cells are permeabilized using 0.2% Triton X-100 (ThermoFisher) in DPBS for 20 minutes at room temperature without shaking. Plates are blocked with antibody diluting buffer (ADB) containing 2% bovine serum albumin (BSA) in DPBS for 1 h at room temperature. Then, plates are incubated overnight at 4°C with gentle shaking in ADB containing a chicken anti-MAP2 antibody (1 : 10,000; EnCor, CPCA-MAP2). The next day, plates are washed three times with DPBS and once with 2% ADB in DPBS.
  • ADB antibody diluting buffer
  • BSA bovine serum albumin
  • Plates are incubated for 1 h at room temperature in ADB containing an anti-chicken IgG secondary antibody conjugated to Alexa Fluor 488 (Life Technologies, 1 : 500) and washed five times with DPBS. After the final wash, 100 pL of DPBS is added per well and imaged on an ImageXpress Micro XL High-Content Screening System (Molecular Devices, Sunnyvale, CA) with a 20x objective.
  • Alexa Fluor 488 Life Technologies, 1 : 500
  • Images are analyzed using ImageJ Fiji (version 1.51W).
  • images corresponding to each treatment are sorted into individual folders that are then blinded for data analysis.
  • Plate controls both positive and negative are used to ensure that the assay is working properly as well as to visually determine appropriate numerical values for brightness/contrast and thresholding to be applied universally to the remainder of the randomized images.
  • the brightness/contrast settings are applied, and approximately 1-2 individual pyramidal-like neurons per image (i.e., no bipolar neurons) are selected using the rectangular selection tool and saved as separate files. Neurons are selected that did not overlap extensively with other cells or extend far beyond the field of view.
  • the threshold settings are then applied to the individual images.
  • Example B-6 Spinogenesis Experiments.
  • Example B-7 Serotonin 5-HT2A In Vitro Radioligand Binding Competition Assay.
  • the 5-HT2A radioligand binding competition assay was performed at Epics Therapeutics S.A. (Belgium, FAST-0505B) using conventional methods. Briefly, competition binding was performed in duplicate in the wells of a 96 well plate (Master Block, Greiner, 786201) containing binding buffer (optimized for each receptor), membrane extracts (amount of protein/well optimized for each receptor), radiotracer [ 3 H]-DOI (final concentration optimized for each receptor) and test compound. Nonspecific binding was determined by co-incubation with 200-fold excess of cold competitor. The samples were incubated in a final volume of 0.1 ml at a temperature and for a duration optimized for each receptor and then filtered over filter plates.
  • Example B-8 Serotonin 5-HT2A In Vitro Cellular IPOne Agonism Assay.
  • the 5-HT2A IPOne HTRF assay was performed at Epics Therapeutics S.A. (Belgium, FAST-05051) using conventional methods. Briefly, CHO-K1 cells expressing human recombinant 5-HT2A receptor grown to mid-log phase in culture media without antibiotics were detached with PBS-EDTA, centrifuged, and resuspended in medium without antibiotics buffer. 20,000 cells are distributed in a 96 well plate and incubated overnight at 37°C with 5% CO2.
  • Example B-9 Serotonin 5-HT2C In Vitro Radioligand Binding Competition Assay.
  • the 5-HT2Cedited (accession number AAF35842.1) radioligand binding competition assay was performed at Epics Therapeutics S.A. (Belgium, FAST-0507B) using conventional methods. Briefly, competition binding was performed in duplicate in the wells of a 96 well plate (Master Block, Greiner, 786201) containing binding buffer (optimized for each receptor), membrane extracts (amount of protein/well optimized for each receptor), radiotracer [ 3 H]-D0I (final concentration optimized for each receptor) and test compound. Nonspecific binding was determined by co-incubation with 200-fold excess of cold competitor.
  • the samples were incubated in a final volume of 0.1 ml at a temperature and for a duration optimized for each receptor and then filtered over filter plates. Filters were washed six times with 0.5 ml of ice-cold washing buffer (optimized for each receptor) and 50 pl of Microscint 20 (Packard) were added in each well. The plates were incubated 15 min on an orbital shaker and then counted with a TopCountTM for 1 min/well.
  • Example B-10 Serotonin 5-HT2C In Vitro Cellular IPOne Agonism Assay.
  • the 5-HT2C IPOne HTRF assay was performed at Epics Therapeutics S.A. (Belgium, FAST-05071) using conventional methods. Briefly, CHO-K1 cells expressing human recombinant 5-HT2Cedited receptor (accession number AAF35842.1) grown to mid-log phase in culture media without antibiotics were detached with PBS-EDTA, centrifuged, and resuspended in medium without antibiotics buffer. 20,000 cells are distributed in a 96 well plate and incubated overnight at 37°C with 5% CO 2 .
  • A: IC50 or EC50 is ⁇ 0.010 pM; B: IC50 or EC50 is 0.010 pM - 0.100 pM; C: IC50 or EC50 is 0.101 pM - 1 pM; D: IC50 or EC50 is 1.001 pM - 10 pM; E: IC50 or EC50 is >10 pM
  • Example B-ll Serotonin 5-HT2A In Vitro Cellular IPOne Antagonism Assay.
  • the 5-HT2A IPOne HTRF assay was performed at Epics Therapeutics S. A. (Belgium, FAST-05051) in antagonism mode using conventional methods. Briefly, CHO-K1 cells expressing human recombinant 5-HT2A receptor grown to mid-log phase in culture media without antibiotics were detached with PBS-EDTA, centrifuged, and resuspended in medium without antibiotics buffer. 20,000 cells were distributed in a 96 well plate and incubated overnight at 37°C with 5% CO 2 .
  • a reference agonist a-Me-5HT was added and fluorescence signal monitored for several minutes, followed by addition of 20 pl of assay buffer plus 20pl of test compound or reference antagonist ketanserin, in each well. The plate was incubated for 60 min. at 37°C with 5% CO 2 .
  • A: IC50 or EC50 is ⁇ 0.010 pM; B: IC50 or EC50 is 0.010 pM - 0.100 pM; C: IC50 or EC50 is 0.101 pM - 1 pM; D: IC50 or EC50 is 1.001 pM - 10 pM; E: IC50 or EC50 is >10 pM
  • Example B-12 Neurite Outgrowth Assay. Neurite Outgrowth in Primary Neuronal Cultures Assay.
  • Pregnant Wistar rats (Janvier; France) were used for the study. They were delivered 6 days before their use. Upon arrival at Neurofit animal facility, they were housed one per cage and maintained in a room with controlled temperature (21-22°C) and a reversed light-dark cycle (12h/12h; lights on: 17:30 - 05:30; lights off: 05:30 - 17:30) with food and water available ad libitum.
  • the suspension was triturated with a 10-ml pipette and using a needle syringe 21G and centrifuged at 350 x g for 10 min at room temperature.
  • the pellet of dissociated cells was resuspended in a medium consisting of Neurobasal (Gibco) supplemented with 2% B27 supplement (Gibco), 0.5mM L-Glutamine (Gibco), an antibiotic-antimicotic mixture.
  • Viable cells were counted in a Neubauer cytometer using the trypan blue exclusion test (Sigma). Cells were seeded at a density of 10000 cells per well in 96-well plate (Costar) precoated with poly-L-lysine. Test compound at different concentrations were added to the cultures. Donepezil (positive control) was tested at 250 nM.
  • nuclei were staining with DAPI 1 mg/ml at 1/1000 in PBS containing 0.5% of BSA. After rinsing with PBS, the plate was filmed and neurite networks were examined and analyzed using High-Content Screening (Celllnsight, Thermo Scientific). The average number of neurites per neuron and the average total length of neurites per neuron were the main parameters analyzed. Analysis of data was performed using analysis of variance (ANOVA). The Fisher’s Protected Least Significant Difference test was used for multiple comparisons. A p value ⁇ 0.05 was considered significant. The software used is StatView 5.0 from SAS Institut. [00302] In some embodiments, a compound of the present disclosure increases the pattern of neurite outgrowth.
  • a compound of the present disclosure increases neurite average length compared to a control. In some embodiments, a compound of the present disclosure increases neurite branch points compared to a control. In some embodiments, a compound of the present disclosure significantly increases the number of new neurites and/or the average neurite length compared to a control.
  • Example B-13 5HTIA Sensor Assays.
  • HEK293T ATCC
  • 5HT2A sensor stable line (sLightl.3s) is generated via lentiviral transduction of HIV-EF I a-sLight l .3 and propagated from a single colony. Lentivirus is produced using 2 nd generation lentiviral plasmids pHIV-EF I a -sLightl.3, pHCMV-G, and pCMV-deltaR8.2.
  • sLightl.3s cells are plated in 96-well plates at a density of 40000 24- hours prior to imaging.
  • images are taken before and after addition of 20/IL of 900nM 5-HT and again after 20 L of the compound working solutions to produce final concentrations of lOOnM for 5HT and 100//M, 10//M and lOOnM for the compounds with a DMSO concentration of 0.1%.
  • Compounds are tested in triplicates (3 wells) for each concentration (100//M, 10//M and lOOnM). Additionally, within each plate, lOOnM 5HT and 0.1% DMSO controls are also imaged.
  • Imaging is performed using the Leica DMi8 inverted microscope with a 40x objective using the FITC preset with an excitation of 460nm and emission of 512-542nm.
  • the cellular membrane where the 5HT2A sensor is targeted is autofocused using the adaptive focus controls and 5 images from different regions within the well are taken with each image processed from a 2x2 binning.
  • dFF (Fsat - Fapo)/ Fapo
  • Inactivation score (dFFF(Compound+5HT) - dFF(5HT))/dFF(5HT)
  • mice are habituated in the test cage for at least 30 min, injected intraperitoneally with compound (injection volume 5 ml/kg), returned to the empty test cage, and filmed for 20 minutes. Each video is scored for the number of head-twitches by a trained observer blinded to treatment condition.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés, des compositions et des procédés pour favoriser la croissance neuronale et/ou améliorer la structure neuronale avec les composés et les compositions de l'invention. L'invention concerne également des méthodes de traitement de maladies ou de troubles qui sont médiés par la perte de connectivité et/ou de plasticité synaptique, telles que des maladies et des troubles neurologiques, avec de la tétrahydroazépine fusionnée ou des psychoplastogènes de pipéridine fusionnés.
PCT/US2024/033653 2023-06-13 2024-06-12 Psychoplastogènes de tétrahydroazépine fusionnés et leurs utilisations Pending WO2024258995A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363507964P 2023-06-13 2023-06-13
US63/507,964 2023-06-13

Publications (2)

Publication Number Publication Date
WO2024258995A2 true WO2024258995A2 (fr) 2024-12-19
WO2024258995A3 WO2024258995A3 (fr) 2025-04-10

Family

ID=93852872

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033653 Pending WO2024258995A2 (fr) 2023-06-13 2024-06-12 Psychoplastogènes de tétrahydroazépine fusionnés et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2024258995A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2402472A1 (fr) * 2000-03-14 2001-10-04 Michael Dalton Ennis Composes a base de 2,3,4,5-tetrahydro-1h-¬1,4|diazepino¬1,7a|indole
WO2004113300A1 (fr) * 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. Nouveau compose heterocyclique tricyclique
MX368362B (es) * 2009-02-05 2019-09-30 Immunogen Inc Derivados novedosos de benzodiacepina.
US20140163012A1 (en) * 2012-12-11 2014-06-12 Albany Molecular Research, Inc. Pyrido-/azepino-benzofuran and pyrido-/azepino-benzothiophene mch-1 antagonists, methods of making, and use thereof
IL305059A (en) * 2021-02-08 2023-10-01 Univ Columbia Oxa-Ibogaine-Inspired Analogues for the Treatment of Neurological and Psychiatric Diseases

Also Published As

Publication number Publication date
WO2024258995A3 (fr) 2025-04-10

Similar Documents

Publication Publication Date Title
WO2021252692A1 (fr) Psychoplastogènes d'isotryptamine et leurs utilisations
WO2021076572A1 (fr) Composés de type ergoline pour favoriser la plasticité neuronale
EP4448532A1 (fr) Psychoplastogènes de pyrrolidine fusionnée et leurs utilisations
AU2020229779A1 (en) Azepino-indoles and other heterocycles for treating brain disorders
WO2021252691A1 (fr) Psychoplastogènes tricycliques et leurs utilisations
AU2022258453A1 (en) Tetracyclic compounds for treating brain disorders
US20250235463A1 (en) Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
WO2023114238A1 (fr) Aryloxy psychoplastogènes et leurs utilisations
WO2023114858A1 (fr) Psychoplastogènes à base de benzofurane et de benzothiophène et leurs utilisations
WO2024258995A2 (fr) Psychoplastogènes de tétrahydroazépine fusionnés et leurs utilisations
WO2024258988A2 (fr) Composés de libération de sérotonine et leurs utilisations
WO2023114325A1 (fr) Psychoplastogènes aminés contraints et leurs utilisations
WO2023114844A1 (fr) Psychoplastogènes d'imidazopyridine et leurs utilisations
CN118696047A (zh) 稠合吡咯烷精神重塑剂及其用途
CN118742551A (zh) 苯氧基和苄氧基取代的精神重塑剂及其用途
CN116507625A (zh) 异色胺神经可塑剂及其用途